MAGL inhibitors
Patent Information
- Application Number
- JP2023524567
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-13
- Filing Date
- 2021-11-12
- Publication Date
- 2024-11-20
- Estimated Expiration
- 2041-11-12
AI Technical Summary
There is a shortage of potent, effective, and selective inhibitors of monoacylglycerol lipase (MAGL) for the treatment of neurological and psychiatric disorders associated with diseases or disorders that benefit from inhibiting MAGL activation, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, epilepsy, pain, migraines, addiction, anxiety, depression, and neuroinflammation.
Development of compounds represented by formula (I), which are MAGL inhibitors, including specific structures such as 1,1,1,3,3,3-hexafluoropropan-2-yl(±)1-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate, to modulate endocannabinoid system signaling and treat associated disorders.
The compounds effectively inhibit MAGL activity, providing therapeutic benefits for neurological and psychiatric disorders by reducing severity, delaying onset, or shortening duration of symptoms.
Smart Images

Figure 2022101412000001 
Figure 2022101412000002 
Figure 2022101412000003
Abstract
Description
[Technical Field]
[0001] The present invention relates to compounds that are monoacylglycerol lipase (MAGL) inhibitors. Another aspect of the invention relates to pharmaceutical compositions containing said compounds and the use of the compounds for treating diseases and disorders associated with modulation of endocannabinoid system signaling activity. [Background technology]
[0002] MAGL is a member of the serine hydrolase superfamily. MAGL is expressed throughout the brain, including neurons, microglia, astrocytes, and oligodendrocytes. MAGL is the primary enzyme controlling the breakdown of 2-arachidonoylglycerol (2-AG) to arachidonic acid (AA) (Blankman et al. Chem Biol. 2007; Nomura et al. Science. 2011).
[0003] 2-AG is the most abundant endocannabinoid ligand in the brain, where it functions as a retrograde messenger that reduces excessive neurotransmission via activation of presynaptic CB1 receptors (Kano et al. Physiol Rev. 2009; Katona and Freund. Physiol Rev. 2009), modulates immune responses by activating microglial CB2 receptors (Turcotte et al. Cell Mol Life Sci. 2016), and promotes neuroprotection, for example, through its effects on oligodendrocyte production and survival (Ilyasov et al. Front Neurosci. 2018).
[0004] AA is one of the most abundant fatty acids in the brain and is the major precursor of eicosanoids, such as prostanoids and leukotrienes, which are known inflammatory mediators.
[0005] MAGL lies at the crossroads between the endocannabinoid and eicosanoid signaling systems. Inhibiting the activity or activity of MAGL is a promising therapeutic approach for preventing or treating brain disorders whose pathological characteristics include hyperneuronal transmission, neuroinflammation, or neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), traumatic brain injury, stroke, epilepsy, pain, migraine, addiction, anxiety, depression, and other stress-related disorders (Grabner et al. Pharmacol Ther. 2017; Mulvihill et al. Life Sci. 2013; Gil-Ordonez et al. Biochem Pharmacol. 2018).
[0006] WO 2019 / 046318 discloses spirocyclic compounds that are MAGL inhibitors.
[0007] WO 2019 / 046330 discloses spirocyclic compounds that are MAGL inhibitors.
[0008] Despite advances in MAGL research, there remains a lack of compounds that are potent, effective, and selective inhibitors of MAGL and that are effective in treating neurological and psychiatric disorders associated with diseases or disorders that benefit from inhibiting MAGL activation. Summary of the Invention
[0009] The object of the present invention is to provide compounds that inhibit MAGL. Accordingly, the present invention provides compounds of formula (I): [ka] (In the formula, R1 represents -C(O)NHR2, -C(O)N(CH3)R2, -C(O)NR3R4, -C(O)NHCH2R2, or -C(O)NHC(O)R2; R2 represents phenyl, or a 5- or 6-membered heteroaryl having 1 or 2 heteroatoms independently selected from N, O, and S, a 6-membered heterocycle having 1 or 2 heteroatoms independently selected from N or O, a C3-C7 cycloalkyl, or a 7-membered bicyclic heterocycle having 1 or 2 heteroatoms independently selected from N or O; R3 and R4 together with the N to which they are attached form a 9- or 10-membered bicyclic heterocycle having 1 to 4 heteroatoms independently selected from N or O, or a 6-membered heterocycle having 1 or 2 heteroatoms independently selected from N or O; or a pharmaceutically acceptable salt thereof, wherein each phenyl, 5- or 6-membered heteroaryl, 6-membered heterocycle, C-C cycloalkyl, 7-membered bicyclic heterocycle, or 9- or 10-membered bicyclic heterocycle is unsubstituted or substituted with one or two substituents independently selected from halogen, C-C alkyl, C-C haloalkyl, C-C cycloalkyl, C-C alkoxy, cyano, —NHC(O)CH, —C(O)NH, —C(O)NHCH, 5-membered heteroaryl having one or two heteroatoms independently selected from N or O, —NHSOCH, —P(O)(CH), and —OCHCOOH.
[0010] In a further aspect of the present invention, there is provided a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers or diluents.
[0011] In a further aspect of the present invention there is provided a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of a disease or disorder selected from pain, epilepsy / seizure disorders, Alzheimer's disease, Huntington's chorea, Huntington's disease, multiple sclerosis, obsessive-compulsive disorder, Parkinson's disease, depression, post-traumatic stress disorder, generalized anxiety disorder, and dystonia.
[0012] In a further aspect of the present invention, there is provided a method for treating a neurological and / or psychiatric disorder selected from pain, epilepsy / seizure disorders, Alzheimer's disease, Huntington's chorea, Huntington's disease, multiple sclerosis, obsessive-compulsive disorder, Parkinson's disease, depression, post-traumatic stress disorder, generalized anxiety disorder, and dystonia, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
[0013] In a further aspect of the invention there is provided the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease or disorder selected from pain, epilepsy / seizure disorders, Alzheimer's disease, Huntington's chorea, Huntington's disease, multiple sclerosis, obsessive-compulsive disorder, Parkinson's disease, depression, post-traumatic stress disorder, generalized anxiety disorder, and dystonia.
[0014] Other objects and advantages of the compounds described herein will become apparent from the following detailed description. However, since various changes and modifications within the spirit and scope of the present disclosure will become apparent to those skilled in the art from this detailed description, it should be understood that the detailed description and specific examples, while indicating specific embodiments, are provided by way of illustration only. The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All documents or portions of documents, including but not limited to patents, patent applications, articles, books, procedural manuals, and papers, are expressly incorporated by reference into this application for all purposes.
[0015] Incorporation by Reference All publications and patent applications mentioned herein are incorporated by reference, to the extent applicable and relevant. [Brief explanation of the drawings]
[0016] [Figure 1]Antinociceptive effect of Example 6 in the rat formalin model; y-axis: counts - hind paw licking frequency; x-axis: duration (min). Significance levels for post-hoc comparisons (compared to vehicle group) are indicated: *p<0.05, **p<0.01, ***p<0.001. [Figure 2] Antinociceptive effect of Example 8 in the rat formalin model; y-axis: counts - hind paw licking frequency; x-axis: duration (min). Significance levels for post-hoc comparisons (compared to vehicle group) are indicated: *p<0.05, **p<0.01, ***p<0.001. [Figure 3] Effect of Example 6 in the MEST model; y-axis: estimated epileptic seizure threshold (CC50) current (mA); significance levels for post-hoc comparisons (vs. vehicle group) are indicated: ***p<0.001. [Figure 4] Effect of Example 8 in the MEST model; y-axis: estimated epileptic seizure threshold (CC50) current (mA); significance levels for post-hoc comparisons (vs. vehicle group) are indicated: ***p<0.001. [Figure 5] Effect of Example 6 in the kainic acid seizure model; y-axis; Counts - number of animals from a group of 12 showing forelimb clonus. Significance levels for post-hoc comparisons (compared to vehicle group) are indicated: **<0.01, ***<0.001. [Figure 6] Effect of Example 8 in the kainic acid epileptic seizure model; y-axis; Counts - number of animals from a group of 12 showing forelimb clonus. Significance levels for post-hoc comparisons (compared to vehicle group) are indicated: ***<0.001. DETAILED DESCRIPTION OF THE INVENTION
[0017] Detailed Description of the Invention definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the claimed subject matter belongs. It is to be understood that the foregoing general description and the following detailed description are for purposes of illustration and explanation only and are not intended to limit the claimed subject matter. In this application, the use of the singular includes the plural unless expressly stated otherwise. It should be noted that as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. In this application, the use of "or" means "and / or" unless expressly stated otherwise. Furthermore, the use of the term "including," as well as other forms such as "include," "includes," and "included," is not limiting.
[0018] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All documents or portions of documents, including but not limited to patents, patent applications, articles, books, procedural manuals, and treatises, are expressly incorporated by reference into this application for all purposes.
[0019] As used herein, the term "acceptable" or "pharmaceutically acceptable" with respect to a formulation, composition, or ingredient means that it does not have a lasting adverse effect on the general health of the subject being treated or that it does not neutralize the biological activity or properties of the compound, and is relatively non-toxic.
[0020] As used herein, "amelioration" of a particular disease, disorder, or condition by administration of a particular compound or pharmaceutical composition refers to a reduction in severity, delay in onset, delay in progression, or shortened duration, whether permanent or temporary, lasting or transient, that can result from or be associated with administration of the compound or composition.
[0021] The term "anti-nociceptive effect", as used herein, relates to the ability of a compound to increase tolerance to pain, treat, delay and / or alleviate pain in a subject.
[0022] Terms like "co-administration," as used herein, are intended to encompass the administration of selected therapeutic agents to one patient and are intended to include therapeutic regimens in which the agents are administered by the same or different routes of administration or at the same or different times.
[0023] The term "effective amount" or "therapeutically effective amount," as used herein, refers to a sufficient quantity of an administered drug or compound to relieve to some extent one or more symptoms of the disease or condition being treated. The result can be a reduction and / or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. For example, an "effective amount" for therapeutic use is the amount of a composition comprising a compound disclosed herein required to provide a clinically significant reduction in disease symptoms without undue adverse side effects. An appropriate "effective amount" in any individual case may be determined using techniques such as dose escalation studies. The term "therapeutically effective amount" includes, for example, a prophylactically effective amount. An "effective amount" of a compound disclosed herein is an amount effective to achieve a desired pharmacological effect or therapeutic improvement without undue adverse side effects. It is understood that an "effective amount" or "therapeutically effective amount" may vary from subject to subject, depending on variability in the metabolism of Compound (I), the subject's age, weight, general condition, the condition being treated, the severity of the condition being treated, and the judgment of the prescribing physician. By way of example only, a therapeutically effective amount may be determined by routine experimentation, including, but not limited to, a dose escalation clinical trial.
[0024] As used herein, the terms "inhibits," "inhibiting," or "inhibitor" of an enzyme, as used herein, refer to the inhibition of enzyme activity.
[0025] The term "isolated," as used herein, refers to the separation and removal of a component of interest from components that are not of interest. An isolated material can be in either a dry or semi-dry state, or in a solution, including but not limited to an aqueous solution. An isolated component can be in a homogeneous state, or the isolated component can be part of a pharmaceutical composition that includes additional pharmaceutically acceptable carriers and / or excipients.
[0026] The term "modulate," as used herein, means to interact directly or indirectly with a target so as to alter the activity of the target, including, by way of example only, enhancing the activity of the target, inhibiting the activity of the target, limiting the activity of the target, or extending the activity of the target.
[0027] As used herein, the term "modulator," as used herein, refers to a compound that alters the activity of a molecule. For example, a modulator can cause an increase or decrease in the magnitude of a particular activity of a molecule compared to the magnitude of the activity in the absence of the modulator. In certain embodiments, a modulator is an inhibitor that decreases the magnitude of one or more activities of a molecule. In certain embodiments, an inhibitor completely prevents one or more activities of a molecule. In certain embodiments, a modulator is an activator that increases the magnitude of at least one activity of a molecule. In certain embodiments, the presence of a modulator results in an activity that does not occur in the absence of the modulator.
[0028] The term "prophylactically effective amount," as used herein, refers to that amount of a composition applied to a patient which will relieve to some extent one or more of the symptoms of the disease, condition, or disorder being treated. In such prophylactic applications, such amount may depend on the patient's state of health, weight, and the like. It is considered well within the skill of one in the art for one to determine such prophylactically effective amounts by routine experimentation, including, but not limited to, dose escalation clinical trials.
[0029] As used herein, the term "subject," as used herein, refers to an animal that has been the object of treatment, observation, or experiment. By way of example only, the subject may be a mammal, including, but not limited to, a human.
[0030] The term "target activity" as used herein refers to a biological activity that can be modulated by a selective modulator. Specific exemplary target activities include, but are not limited to, binding affinity, signal transduction, enzyme activity, tumor growth, inflammation or inflammation-related processes, and amelioration of one or more symptoms associated with a disease or condition.
[0031] The terms "treat," "treating," or "treatment," as used herein, include alleviating, reducing, or ameliorating a disease or condition, such as preventing the onset of a disease or condition, relieving a disease or condition, causing regression of a disease or condition, alleviating symptoms caused by a disease or condition, or halting the symptoms of a disease or condition, preventing additional symptoms, ameliorating or preventing the underlying metabolic cause of a symptom, inhibiting a disease or condition. The terms "treat," "treating," or "treatment" include, but are not limited to, prophylactic and / or therapeutic treatments.
[0032] I C 50 As used herein, refers to the amount, concentration, or dose of a particular test compound that achieves 50% inhibition of a maximal response, such as inhibition of MAGL, in an assay that measures such response.
[0033] EC 50 As used herein, refers to the dose, concentration, or amount of a particular test compound that elicits a dose-dependent response of 50% of the maximum expression of a particular response induced, elicited, or potentiated by the particular test compound.
[0034] The term "alkyl," as used herein, refers to a straight-chain (i.e., unbranched) or branched saturated hydrocarbon having from 1 to 8 carbon atoms. The term "C1-C3 alkyl" means a straight-chain or branched hydrocarbon containing from 1 to 3 carbon atoms. Representative examples of alkyl include, but are not limited to, methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2-methyl-2-propyl, 2-methyl-1-butyl, n-hexyl, n-heptyl, and n-octyl.
[0035] The term "alkylene," as used herein, refers to a divalent group derived from a straight or branched chain hydrocarbon of from 1 to 10 carbon atoms. Representative examples of alkylene include, but are not limited to, -CH-, -CHCH-, -CHCHCH-, -CHCH(CH)CH-, -CHCHCHCH-, -CHCH(CH)CHCH-, -CH(CH)-, and -CHCHCHCHCHCH-.
[0036] The term "alkoxy" refers to a moiety of the formula -OR', where R' represents alkyl as defined above. 1~ "C3 alkoxy" refers to such a moiety where the alkyl portion has 1, 2 or 3 carbon atoms. 1~ Examples of "C3 alkoxy" include methoxy, ethoxy, n-propoxy, and isopropoxy.
[0037] The term "cycloalkyl," as used herein, refers to a saturated ring system containing all carbon atoms as ring members and no double bonds. Cycloalkyls may be monocyclic cycloalkyls (e.g., cyclopropyl), preferably having 3 to 7 carbon atoms in the ring.
[0038] The term "halogen" is intended to indicate a substituent selected from main group 7 of the periodic table, such as, for example, fluoro, chloro or bromo.
[0039] The terms "haloalkyl" or "haloalkoxy" are intended to refer to an alkyl or alkoxy group, as defined above, in which one, two, or three hydrogens have been replaced with a halogen.
[0040] Similarly, the term "fluoroalkyl" is intended to refer to an alkyl group as defined above in which one, two, or three hydrogens have been replaced with fluoro. One example of such a group is trifluoromethyl.
[0041] As used herein, the term "hydroxyl" or "hydroxy" refers to an --OH group as used herein.
[0042] The term "hydroxyalkyl," as used herein, means at least one --OH group attached to the parent molecular moiety through an alkylene group, as defined herein.
[0043] The term "hydroxyhaloalkyl," as used herein, means at least one --OH group attached to the parent molecular moiety through a haloalkyl group, as defined herein.
[0044] The term "hydroxyfluoroalkyl," as used herein, means at least one --OH group attached to the parent molecular moiety through a fluoroalkyl group, as defined herein.
[0045] The term "oxo," as used herein, refers to an oxygen atom attached to another atom by a double bond. When the atom to which the oxygen is attached is attached to a carbon, the carbonyl group formed is depicted as -(CO)-.
[0046] The term "5-membered heteroaryl" refers to a 5-membered aromatic ring in which one, two, or three ring atoms are selected from O, N, or S. Examples of 5-membered heteroaryls of the present invention include thiophenyl, pyrrolyl, furanyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyloxadiazolyl, and thiadiazolyl.
[0047] The term "6-membered heteroaryl" refers to a 6-membered aromatic ring in which one, two, or three ring atoms are independently selected from O, N, or S. Examples of 6-membered heteroaryls of the present invention include, but are not limited to, pyridyl, pyridazinyl, pyrimidinyl, pyranyl, diazinyl, and triazinyl.
[0048] The terms "monocyclic heterocycle," "monoheterocycle," and "monoheterocycle," as used herein, alone or in combination, refer to a saturated or unsaturated non-aromatic ring containing 5 to 6 ring atoms, in which one or more of the ring atoms is a heteroatom. In some embodiments of the present invention, heterocycle is intended to mean a 6-membered ring structure having one or two heteroatoms independently selected from N or O. Examples of 6-membered heterocycles include, but are not limited to, tetrahydropyranyl, piperidinyl, and morpholinyl.
[0049] The term "bicyclic heterocycle," as used herein, refers to a monocyclic ring attached to a parent moiety to form a fused, spiro, or bridged ring system with a cycloalkyl group, a monocyclic heterocycle, a benzene ring, or a monocyclic 5- or 6-membered heteroaryl. The term "7-membered bicyclic heterocycle" refers to a bicyclic heterocycle as defined above having 7 ring atoms and containing at least one heteroatom selected from N, O, or S. Examples of 7-membered bicyclic heterocycles include, but are not limited to, 2-oxaspiro[3.3]heptan-6-yl. The term "9- or 10-membered bicyclic heterocycle" refers to a bicyclic heterocycle as defined above having 9 or 10 ring atoms and containing at least one heteroatom selected from N, O, or S. Examples of 9- or 10-membered bicyclic heterocycles include, but are not limited to, 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazinyl, 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidinyl, 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidinyl, 2-cyclopropyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidinyl, 3-cyclopropyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazinyl, or 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidinyl.
[0050] Embodiments of the present invention In a first embodiment, the present invention provides a compound of formula (I): [ka] (In the formula, R1 represents -C(O)NHR2, -C(O)N(CH3)R2, -C(O)NR3R4, -C(O)NHCH2R2, or -C(O)NHC(O)R2; R2 represents phenyl, or a 5- or 6-membered heteroaryl having 1 or 2 heteroatoms independently selected from N, O, and S, a 6-membered heterocycle having 1 or 2 heteroatoms independently selected from N or O, a C3-C7 cycloalkyl, or a 7-membered bicyclic heterocycle having 1 or 2 heteroatoms independently selected from N or O; R3 and R4 together with the N to which they are attached form a 9- or 10-membered bicyclic heterocycle having 1 to 4 heteroatoms independently selected from N or O, or a 6-membered heterocycle having 1 or 2 heteroatoms independently selected from N or O; or a pharmaceutically acceptable salt thereof, wherein each phenyl, 5- or 6-membered heteroaryl, 6-membered heterocycle, C3-C7 cycloalkyl, 7-membered bicyclic heterocycle, or 9- or 10-membered bicyclic heterocycle is unsubstituted or substituted by one or two substituents independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C3-C6 cycloalkyl, C1-C3 alkoxy, cyano, —NHC(O)CH3, —C(O)NH2, —C(O)NHCH3, 5-membered heteroaryl having one or two heteroatoms independently selected from N or O, —NHSO2CH3, —P(O)(CH3)2, and —OCH2COOH.
[0051] In a further embodiment, the compound of the present invention has formula (Ia): [ka] (In the formula, R1 represents -C(O)NHR2, -C(O)N(CH3)R2, -C(O)NR3R4, -C(O)NHCH2R2, or -C(O)NHC(O)R2; R2 represents phenyl, or a 5- or 6-membered heteroaryl having 1 or 2 heteroatoms independently selected from N, O, and S, a 6-membered heterocycle having 1 or 2 heteroatoms independently selected from N or O, a C3-C7 cycloalkyl, or a 7-membered bicyclic heterocycle having 1 or 2 heteroatoms independently selected from N or O; R3 and R4 together with the N to which they are attached form a 9- or 10-membered bicyclic heterocycle having 1 to 4 heteroatoms independently selected from N or O, or a 6-membered heterocycle having 1 or 2 heteroatoms independently selected from N or O; Each phenyl, 5- or 6-membered heteroaryl, 6-membered heterocycle, C-C cycloalkyl, 7-membered bicyclic heterocycle, or 9- or 10-membered bicyclic heterocycle is unsubstituted or substituted with one or two substituents independently selected from halogen, C-C alkyl, C-C haloalkyl, C-C cycloalkyl, C-C alkoxy, cyano, —NHC(O)CH, —C(O)NH, —C(O)NHCH, 5-membered heteroaryl having one or two heteroatoms independently selected from N or O, —NHSOCH, —P(O)(CH), and —OCHCOOH, or a pharmaceutically acceptable salt thereof.
[0052] In a further embodiment, the compound of the invention has formula (Ib): [ka] (In the formula, R1 represents -C(O)NHR2, -C(O)N(CH3)R2, -C(O)NR3R4, -C(O)NHCH2R2, or -C(O)NHC(O)R2; R2 represents phenyl, or a 5- or 6-membered heteroaryl having 1 or 2 heteroatoms independently selected from N, O, and S, a 6-membered heterocycle having 1 or 2 heteroatoms independently selected from N or O, a C3-C7 cycloalkyl, or a 7-membered bicyclic heterocycle having 1 or 2 heteroatoms independently selected from N or O; R3 and R4 together with the N to which they are attached form a 9- or 10-membered bicyclic heterocycle having 1 to 4 heteroatoms independently selected from N or O, or a 6-membered heterocycle having 1 or 2 heteroatoms independently selected from N or O; Each phenyl, 5- or 6-membered heteroaryl, 6-membered heterocycle, C-C cycloalkyl, 7-membered bicyclic heterocycle, or 9- or 10-membered bicyclic heterocycle is unsubstituted or substituted with one or two substituents independently selected from halogen, C-C alkyl, C-C haloalkyl, C-C cycloalkyl, C-C alkoxy, cyano, —NHC(O)CH, —C(O)NH, —C(O)NHCH, 5-membered heteroaryl having one or two heteroatoms independently selected from N or O, —NHSOCH, —P(O)(CH), and —OCHCOOH, or a pharmaceutically acceptable salt thereof.
[0053] In one embodiment of the compounds of Formula (I), (Ia) or (Ib) or a pharmaceutically acceptable salt thereof, wherein R 1 represents —C(O)NHR 2 .
[0054] In one embodiment of a compound of Formula (I), (Ia) or (Ib) or a pharmaceutically acceptable salt thereof, R represents -C(O)NHR; R represents a 5- or 6-membered heteroaryl having 1 or 2 heteroatoms independently selected from N, O, and S; or a 6-membered heterocycle having 1 or 2 heteroatoms independently selected from N or O; and each 5- or 6-membered heteroaryl or 6-membered heterocycle is independently unsubstituted or substituted with one substituent selected from halogen, C-C alkyl, C-C haloalkyl, C-C cycloalkyl, C-C alkoxy, cyano, -NHC(O)CH, -C(O)NH, -C(O)NHCH, 5-membered heteroaryl having 1 or 2 heteroatoms independently selected from N or O, -NHSOCH, -P(O)(CH), and -OCHCOOH.
[0055] In one embodiment of the compounds of Formula (I), (Ia) or (Ib) or pharmaceutically acceptable salts thereof, R represents a 5- or 6-membered heteroaryl selected from the group consisting of pyridyl, pyrazinyl, pyridazinyl, pyrimidyl, pyrazolyl, thiazolyl, and isoxazolyl, wherein said 5- or 6-membered heteroaryl is unsubstituted or substituted with one substituent selected from the group consisting of halogen, C-C alkyl, C-C haloalkyl, cyclopropyl, C-C alkoxy, cyano, —NHC(O)CH, —C(O)NH, —C(O)NHCH, 5-membered heteroaryl having 1 or 2 heteroatoms independently selected from N or O, —NHSOCH, —P(O)(CH), and —OCHCOOH.
[0056] In one embodiment of the compounds of Formula (I), (Ia) or (Ib) or pharmaceutically acceptable salts thereof, R2 represents a 6-membered heterocycle selected from the group consisting of tetrahydro-2H-pyran-4-yl, piperazinyl, and piperidinyl, wherein R2 is unsubstituted or substituted with one substituent selected from the group consisting of C1-C3 alkyl, C3-C6 cycloalkyl, and cyano.
[0057] In one embodiment of the compounds of Formula (I), (Ia) or (Ib) or pharmaceutically acceptable salts thereof, R2 represents a 6-membered heterocycle selected from the group consisting of tetrahydro-2H-pyran-4-yl, piperazinyl, and piperidinyl, and said R2 is unsubstituted.
[0058] In one embodiment of the compounds of Formula (I), (Ia) or (Ib) or pharmaceutically acceptable salts thereof, wherein R2 is selected from the group consisting of: [ka]
[0059] In one embodiment of the compounds of Formula (I), (Ia) or (Ib) or pharmaceutically acceptable salts thereof, wherein R2 is selected from the group consisting of: [ka]
[0060] In one embodiment of a compound of Formula (I), (Ia) or (Ib) or a pharmaceutically acceptable salt thereof, R3 and R4 together with the N to which they are attached form a 9- or 10-membered bicyclic heterocycle selected from the group consisting of 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazinyl, 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidinyl, and 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazinyl, wherein said 9- to 10-membered bicyclic heterocycle is unsubstituted or substituted with one substituent selected from C3-C6 cycloalkyl or C1-C3 haloalkyl.
[0061] In one embodiment of the compounds of Formula (I), (Ia) or (Ib) or pharmaceutically acceptable salts thereof, R3 and R4 together with the N to which they are attached form a 9- to 10-membered bicyclic heterocycle selected from the group consisting of: [ka]
[0062] In a further embodiment, the compound of the invention has formula (Ic): [ka] (In the formula, R5 represents phenyl, or a 5- or 6-membered heteroaryl having 1 or 2 heteroatoms independently selected from N, O, and S, a 6-membered heterocycle, a C3-C7 cycloalkyl, or a 7-membered bicyclic heterocycle having 1 or 2 heteroatoms independently selected from N or O; R6 represents hydrogen or methyl; W is —CH— or —C(O)—; n is 0 or 1; Each phenyl, 5- or 6-membered heteroaryl, 6-membered heterocycle, C3-C7 cycloalkyl, 7-membered bicyclic heterocycle is unsubstituted or substituted by one or two substituents independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C3-C6 cycloalkyl, C1-C3 alkoxy, cyano, —NHC(O)CH3, —C(O)NH2, —C(O)NHCH3, 5-membered heteroaryl having one or two heteroatoms independently selected from N or O, —NHSO2CH3, —P(O)(CH3)2, and —OCH2COOH), or a pharmaceutically acceptable salt thereof.
[0063] In a further embodiment, the compound of the invention has formula (Id): [ka] (In the formula, R5 represents phenyl, or a 5- or 6-membered heteroaryl having 1 or 2 heteroatoms independently selected from N, O, and S, a 6-membered heterocycle, a C3-C7 cycloalkyl, or a 7-membered bicyclic heterocycle having 1 or 2 heteroatoms independently selected from N or O; R6 represents hydrogen or methyl; W is —CH— or —C(O)—; n is 0 or 1; Each phenyl, 5- or 6-membered heteroaryl, 6-membered heterocycle, C3-C7 cycloalkyl, 7-membered bicyclic heterocycle is unsubstituted or substituted by one or two substituents independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C3-C6 cycloalkyl, C1-C3 alkoxy, cyano, —NHC(O)CH3, —C(O)NH2, —C(O)NHCH3, 5-membered heteroaryl having one or two heteroatoms independently selected from N or O, —NHSO2CH3, —P(O)(CH3)2, and —OCH2COOH), or a pharmaceutically acceptable salt thereof.
[0064] In one embodiment of the compounds of Formula (Ic) or (Id), or pharmaceutically acceptable salts thereof, wherein n is 0.
[0065] In one embodiment of the compound of Formula (Ic) or (Id) or a pharmaceutically acceptable salt thereof, R5 represents a 5- or 6-membered heteroaryl selected from the group consisting of pyridyl, pyrazinyl, pyridazinyl, pyrimidyl, pyrazolyl, thiazolyl, and isoxazolyl, wherein said R5 is unsubstituted or substituted with one substituent selected from the group consisting of halogen, C1-C3 alkyl, C1-C3 haloalkyl, cyclopropyl, C1-C3 alkoxy, cyano, —NHC(O)CH3, —C(O)NH2, —C(O)NHCH3, 5-membered heteroaryl having one or two heteroatoms independently selected from N or O, —NHSO2CH3, —P(O)(CH3)2, and —OCH2COOH.
[0066] In one embodiment of the compound of formula (Ic) or (Id) or a pharmaceutically acceptable salt thereof, R5 represents a 6-membered heteroaryl selected from the group consisting of pyridyl, pyrazinyl, pyridazinyl, and pyrimidyl, wherein said 6-membered heteroaryl is unsubstituted.
[0067] In one embodiment of the compound of Formula (Ic) or (Id) or a pharmaceutically acceptable salt thereof, R5 represents a 6-membered heterocycle selected from the group consisting of tetrahydro-2H-pyran-4-yl, piperazinyl, and piperidinyl, wherein said R5 is unsubstituted or substituted with one substituent selected from the group consisting of C1-C3 alkyl, C3-C6 cycloalkyl, and cyano.
[0068] In one embodiment of the compounds of Formula (Ic) or (Id), or pharmaceutically acceptable salts thereof, wherein R5 is unsubstituted.
[0069] In one embodiment of the compounds of Formula (Ic) or (Id) or a pharmaceutically acceptable salt thereof, wherein R5 is selected from the group consisting of: [ka]
[0070] In one embodiment of the compounds of Formula (Ic) or (Id) or a pharmaceutically acceptable salt thereof, wherein R5 is selected from the group consisting of: [ka]
[0071] In one embodiment of the compounds of Formula (Ic) or (Id) or a pharmaceutically acceptable salt thereof, wherein R5 represents 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidinyl 2-oxaspiro[3.3]heptan-6-yl.
[0072] In one embodiment of the compounds of Formula (Ic) or (Id), or pharmaceutically acceptable salts thereof, wherein n is 0.
[0073] In a further embodiment, the compound of the invention has formula (Ie): [ka] (In the formula, R7 represents phenyl, or a 5- or 6-membered heteroaryl having 1 or 2 N atoms, or a 5- or 6-membered heterocycle having one heteroatom selected from N or O; each phenyl, 5- or 6-membered heteroaryl, or 5- or 6-membered heterocycle is unsubstituted or substituted with one substituent selected from the group consisting of halogen, C1-C3 alkyl, C1-C3 haloalkyl, cyclopropyl, C1-C3 alkoxy, and cyano), or a pharmaceutically acceptable salt thereof.
[0074] In a further embodiment, the compound of the invention has the formula (If) [ka] (In the formula, R7 represents phenyl, or a 5- or 6-membered heteroaryl having 1 or 2 N atoms, or a 5- or 6-membered heterocycle having one heteroatom selected from N or O; each phenyl, 5- or 6-membered heteroaryl, or 5- or 6-membered heterocycle is unsubstituted or substituted with one substituent selected from the group consisting of halogen, C1-C3 alkyl, C1-C3 haloalkyl, cyclopropyl, C1-C3 alkoxy, and cyano), or a pharmaceutically acceptable salt thereof.
[0075] In one embodiment of the compounds of Formula (Ie) and (If) or pharmaceutically acceptable salts thereof, R7 represents pyridyl, pyrazinyl, pyridazinyl, pyrimidyl, pyrazolyl, thiazolyl, and isoxazolyl, wherein said R7 is unsubstituted or substituted with one substituent selected from the group consisting of halogen, C1-C3 alkyl, C1-C3 haloalkyl, cyclopropyl, C1-C3 alkoxy, and cyano.
[0076] In one embodiment of the compounds of Formula (Ie) and (If) or pharmaceutically acceptable salts thereof, R7 represents tetrahydro-2H-pyran-4-yl, piperazinyl, and piperidinyl, wherein R7 is unsubstituted or substituted with one substituent selected from the group consisting of C1-C3 alkyl, C3-C6 cycloalkyl, and cyano.
[0077] In one embodiment of the compounds of Formula (Ie) or (If) or a pharmaceutically acceptable salt thereof, R7 represents tetrahydro-2H-pyran-4-yl, piperazinyl, or piperidinyl, wherein said R7 is unsubstituted.
[0078] In a further embodiment, the compound of the invention is selected from the group consisting of: 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((tetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(methyl(pyrazin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(isoxazol-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((2-(trifluoromethyl)pyrimidin-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((6-(dimethylphosphoryl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(pyridin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((tetrahydro-2H-pyran-4-carbonyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((6-(1H-pyrazol-1-yl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((6-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(4-cyclopropylpiperazine-1-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((6-methoxypyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((5-fluoropyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(methyl(pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(methyl(pyridin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(pyridin-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(2-(trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-7-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(pyrazin-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(2-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-7-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-6-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(2-cyclopropyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-6-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((5-chloropyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((2-methylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((6-(trifluoromethyl)pyridin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(((6-(trifluoromethyl)pyridin-2-yl)methyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((6-(trifluoromethyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((6-methylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((2-(trifluoromethyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((pyridin-3-ylmethyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((cyclohexanecarbonyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(benzoylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(pyrimidin-5-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((2-(trifluoromethyl)pyrimidin-5-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((2-methylpyrimidin-5-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((6-methylpyridazin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(pyridazin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((5-methylpyrazin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((1-methylpiperidin-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(((tetrahydro-2H-pyran-4-yl)methyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(morpholine-4-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(4-cyanopiperidine-1-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((1-methyl-1H-pyrazol-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(thiazol-5-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((4-methyltetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((1-methyl-1H-pyrazol-5-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(thiazol-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(phenylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(p-tolylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)-1-((3-fluorophenyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate: 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(benzylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((pyrimidin-5-ylmethyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((pyridazin-3-ylmethyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((2-oxaspiro[3.3]heptan-6-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((6-cyclopropylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((6-isopropoxypyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(((4-methyltetrahydro-2H-pyran-4-yl)methyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((6-acetamidopyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((6-carbamoylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(isoxazol-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((6-(methylsulfonamido)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; (±)2-((5-(6-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-6-azaspiro[2.5]octane-1-carboxamido)pyridin-2-yl)oxy)acetic acid; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(3-cyclopropyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine-7-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-7-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-7-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(methyl(pyridazin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; and 1,1,1,3,3,3-hexafluoropropan-2-yl(±)1-((6-cyanopyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; or a pharmaceutically acceptable salt thereof.
[0079] In a further embodiment, the compound of the invention is selected from the group consisting of: 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(3-cyclopropyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine-7-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-7-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-7-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(methyl(pyridazin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; and 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((6-cyanopyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; or a pharmaceutically acceptable salt thereof.
[0080] In a further embodiment, the compound of the invention is selected from the group consisting of: 1,1,1,3,3,3-Hexafluoropropan-2-yl(R)-1-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((tetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((tetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(R)-1-(methyl(pyrazin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(methyl(pyrazin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(R)-1-(isoxazol-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(isoxazol-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((2-(trifluoromethyl)pyrimidin-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((2-(trifluoromethyl)pyrimidin-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((6-(dimethylphosphoryl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((6-(dimethylphosphoryl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(R)-1-(pyridin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(pyridin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(R)-1-((tetrahydro-2H-pyran-4-carbonyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((tetrahydro-2H-pyran-4-carbonyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((6-(1H-pyrazol-1-yl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((6-(1H-pyrazol-1-yl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((6-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((6-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(R)-1-((6-methoxypyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((6-methoxypyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(R)-1-((5-fluoropyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((5-fluoropyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(R)-1-(methyl(pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(methyl(pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(R)-1-(methyl(pyridin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(methyl(pyridin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(R)-1-(pyridin-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(pyridin-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(2-(trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-7-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(2-(trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-7-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(R)-1-(pyrazin-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(pyrazin-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(2-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-7-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(2-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-7-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-6-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-6-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(2-cyclopropyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-6-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(2-cyclopropyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-6-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((5-chloropyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((5-chloropyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(R)-1-((2-methylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((2-methylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((6-(trifluoromethyl)pyridin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((6-(trifluoromethyl)pyridin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(((6-(trifluoromethyl)pyridin-2-yl)methyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(((6-(trifluoromethyl)pyridin-2-yl)methyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((6-(trifluoromethyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((6-(trifluoromethyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((6-methylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((6-methylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((2-(trifluoromethyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((2-(trifluoromethyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(R)-1-((pyridin-3-ylmethyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((pyridin-3-ylmethyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((cyclohexanecarbonyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((cyclohexanecarbonyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(benzoylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(benzoylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(R)-1-(pyrimidin-5-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(pyrimidin-5-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((2-(trifluoromethyl)pyrimidin-5-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((2-(trifluoromethyl)pyrimidin-5-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((2-methylpyrimidin-5-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((2-methylpyrimidin-5-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((6-methylpyridazin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((6-methylpyridazin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(R)-1-(pyridazin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(pyridazin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((5-methylpyrazin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((5-methylpyrazin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((1-methylpiperidin-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((1-methylpiperidin-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(R)-1-(((tetrahydro-2H-pyran-4-yl)methyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(((tetrahydro-2H-pyran-4-yl)methyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(morpholine-4-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(morpholine-4-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(4-cyanopiperidine-1-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(4-cyanopiperidine-1-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((1-methyl-1H-pyrazol-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((1-methyl-1H-pyrazol-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(R)-1-(thiazol-5-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(thiazol-5-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((4-methyltetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((4-methyltetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((1-methyl-1H-pyrazol-5-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((1-methyl-1H-pyrazol-5-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(R)-1-(thiazol-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(thiazol-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(R)-1-(phenylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(phenylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(p-tolylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(p-tolylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((3-fluorophenyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((3-fluorophenyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(R)-1-(benzylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(benzylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(R)-1-((pyrimidin-5-ylmethyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((pyrimidin-5-ylmethyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(R)-1-((pyridazin-3-ylmethyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((pyridazin-3-ylmethyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(R)-1-((2-oxaspiro[3.3]heptan-6-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((2-oxaspiro[3.3]heptan-6-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((6-cyclopropylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((6-cyclopropylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((6-isopropoxypyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((6-isopropoxypyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(((4-methyltetrahydro-2H-pyran-4-yl)methyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(((4-methyltetrahydro-2H-pyran-4-yl)methyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((6-acetamidopyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((6-acetamidopyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((6-carbamoylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((6-carbamoylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(R)-1-(isoxazol-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(isoxazol-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((6-(methylsulfonamido)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((6-(methylsulfonamido)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; (R)-2-((5-(6-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-6-azaspiro[2.5]octane-1-carboxamido)pyridin-2-yl)oxy)acetic acid; and (S)-2-((5-(6-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-6-azaspiro[2.5]octane-1-carboxamido)pyridin-2-yl)oxy)acetic acid; or a pharmaceutically acceptable salt thereof.
[0081] In a further embodiment, the compound of the invention is selected from the group consisting of: 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((tetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(methyl(pyrazin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(isoxazol-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((2-(trifluoromethyl)pyrimidin-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((6-(dimethylphosphoryl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(pyridin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((tetrahydro-2H-pyran-4-carbonyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((6-(1H-pyrazol-1-yl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((6-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((6-methoxypyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((5-fluoropyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(methyl(pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(methyl(pyridin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(pyridin-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(2-(trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-7-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(pyrazin-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(2-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-7-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-6-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(2-cyclopropyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-6-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((5-chloropyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((2-methylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((6-(trifluoromethyl)pyridin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(((6-(trifluoromethyl)pyridin-2-yl)methyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((6-(trifluoromethyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((6-methylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((2-(trifluoromethyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((pyridin-3-ylmethyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((cyclohexanecarbonyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(benzoylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(pyrimidin-5-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((2-(trifluoromethyl)pyrimidin-5-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((2-methylpyrimidin-5-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((6-methylpyridazin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(pyridazin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((5-methylpyrazin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((1-methylpiperidin-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(((tetrahydro-2H-pyran-4-yl)methyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(morpholine-4-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(4-cyanopiperidine-1-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((1-methyl-1H-pyrazol-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(thiazol-5-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((4-methyltetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((1-methyl-1H-pyrazol-5-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(thiazol-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(phenylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(p-tolylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((3-fluorophenyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(benzylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((pyrimidin-5-ylmethyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((pyridazin-3-ylmethyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((2-oxaspiro[3.3]heptan-6-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((6-cyclopropylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((6-isopropoxypyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(((4-methyltetrahydro-2H-pyran-4-yl)methyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((6-acetamidopyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((6-carbamoylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(isoxazol-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-hexafluoropropan-2-yl(S)-1-((6-(methylsulfonamido)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; and (S)-2-((5-(6-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-6-azaspiro[2.5]octane-6-1-carboxamido)pyridin-2-yl)oxy)acetic acid; or a pharmaceutically acceptable salt thereof.
[0082] In a further embodiment, the compound of the invention is selected from the group consisting of: 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((tetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(pyridin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(pyridin-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(pyrazin-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(pyrimidin-5-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(pyridazin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-hexafluoropropan-2-yl (S)-1-((1-methylpiperidin-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; and 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((4-methyltetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; or a pharmaceutically acceptable salt thereof.
[0083] In one embodiment, the compound of the invention is 1,1,1,3,3,3-hexafluoropropan-2-yl(S)-1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate, or a pharmaceutically acceptable salt thereof.
[0084] In one embodiment, the compound of the invention is 1,1,1,3,3,3-hexafluoropropan-2-yl(S)-1-((tetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate, or a pharmaceutically acceptable salt thereof.
[0085] In one embodiment, the compound of the invention is 1,1,1,3,3,3-hexafluoropropan-2-yl(S)-1-(pyridin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate, or a pharmaceutically acceptable salt thereof.
[0086] In one embodiment, the compound of the invention is 1,1,1,3,3,3-hexafluoropropan-2-yl(S)-1-(pyridin-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate, or a pharmaceutically acceptable salt thereof.
[0087] In one embodiment, the compound of the invention is 1,1,1,3,3,3-hexafluoropropan-2-yl(S)-1-(pyrazin-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate, or a pharmaceutically acceptable salt thereof.
[0088] In one embodiment, the compound of the invention is 1,1,1,3,3,3-hexafluoropropan-2-yl(S)-1-(pyrimidin-5-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate, or a pharmaceutically acceptable salt thereof.
[0089] In one embodiment, the compound of the invention is 1,1,1,3,3,3-hexafluoropropan-2-yl(S)-1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate, or a pharmaceutically acceptable salt thereof.
[0090] In one embodiment, the compound of the invention is 1,1,1,3,3,3-hexafluoropropan-2-yl(S)-1-((tetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate.
[0091] In one embodiment, the compound of the invention is 1,1,1,3,3,3-hexafluoropropan-2-yl(S)-1-(pyridin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate.
[0092] In one embodiment, the compound of the invention is 1,1,1,3,3,3-hexafluoropropan-2-yl(S)-1-(pyridin-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate.
[0093] In one embodiment, the compound of the invention is 1,1,1,3,3,3-hexafluoropropan-2-yl(S)-1-(pyrazin-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate.
[0094] In one embodiment, the compound of the invention is 1,1,1,3,3,3-hexafluoropropan-2-yl(S)-1-(pyrimidin-5-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate.
[0095] In one embodiment, there is provided a pharmaceutical composition comprising a compound of Formula (I), (Ia), (Ib), (Id), (Ie), or (If) or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or diluents.
[0096] In a further embodiment, there is provided a compound of formula (I), (Ia), (Ib), (Id), (Ie), or (If) or a pharmaceutically acceptable salt thereof for use as a medicament.
[0097] In one embodiment, there is provided a compound of Formula (I), (Ia), (Ib), (Id), (Ie), or (If) or a pharmaceutically acceptable salt thereof for use in the treatment of a disease or injury selected from the group consisting of pain, epilepsy / seizure disorders, Alzheimer's disease, Huntington's chorea, Huntington's disease, spasticity, multiple sclerosis, obsessive-compulsive disorder, Parkinson's disease, depression, post-traumatic stress disorder, generalized anxiety disorder, and dystonia.
[0098] In a further embodiment, there is provided a compound of Formula (I), (Ia), (Ib), (Id), (Ie), or (If), or a pharmaceutically acceptable salt thereof, for use in treating pain. In a further embodiment, the pain is neuropathic pain. In one embodiment, the pain is inflammatory pain. In a further embodiment, the pain is selected from the group consisting of acute pain, cancer pain, chronic pain, pain due to peripheral neuropathy, central pain, pain due to spinal cord injury, pain due to stroke, complex regional pain syndrome, fibromyalgia, migraine, vaso-occlusive painful episodes in sickle cell disease, pain associated with sclerosis, low back pain, abdominal pain associated with irritable bowel syndrome, functional chest pain, rheumatoid arthritis, osteoarthritis, somatoform disorder, or functional dyspepsia.
[0099] In one embodiment, there is provided the use of a compound of Formula (I), (Ia), (Ib), (Id), (Ie), or (If) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a disease or injury selected from the group consisting of pain, epilepsy / seizure disorders, Alzheimer's disease, Huntington's chorea, Huntington's disease, spasticity, multiple sclerosis, obsessive-compulsive disorder, Parkinson's disease, depression, post-traumatic stress disorder, generalized anxiety disorder, and dystonia.
[0100] In one embodiment, there is provided a method for treating a disease or injury selected from the group consisting of pain, epilepsy / seizure disorders, Alzheimer's disease, Huntington's chorea, Huntington's disease, spasticity, multiple sclerosis, obsessive-compulsive disorder, Parkinson's disease, depression, post-traumatic stress disorder, generalized anxiety disorder, and dystonia, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Id), (Ie), or (If) or a pharmaceutically acceptable salt thereof.
[0101] The compounds of the present invention are generally utilized as free substances or as their pharmaceutically acceptable salts. When the compound of formula (I) contains a free base, such salts may be prepared in a conventional manner by treating a solution or suspension of the free base of formula (I) with a molar equivalent of a pharmaceutically acceptable acid. Representative examples of suitable organic and inorganic acids are listed below.
[0102] Pharmaceutically acceptable salts in this context are intended to denote non-toxic, i.e. physiologically acceptable salts. The term pharmaceutically acceptable salts includes salts formed with inorganic and / or organic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, nitrous acid, sulfuric acid, benzoic acid, citric acid, gluconic acid, lactic acid, maleic acid, succinic acid, tartaric acid, acetic acid, propionic acid, oxalic acid, maleic acid, fumaric acid, glutamic acid, pyroglutamic acid, salicylic acid; and sulfonic acids such as methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, and benzenesulfonic acid.
[0103] The compounds of the present invention may have one or more asymmetric centers, and any optical isomers (i.e., enantiomers or diastereomers) are intended to be included within the scope of the present invention as separated enantiopure or partially purified optical isomers and as any mixtures thereof, including racemic mixtures, i.e., mixtures of stereoisomers.
[0104] In this context, when specifying an enantiomeric form, it is understood that the compound is in enantiomeric excess, e.g., in essentially enantiopure form. Thus, one embodiment of the present invention relates to a compound of the present invention having an enantiomeric excess (ee) of at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 96%, preferably at least 98%.
[0105] Racemic forms can be resolved into their optical antipodes by known methods, such as separation of diastereomeric salts with an optically active acid and liberation of the optically active amine compound by treatment with a base. Another method for optically resolving racemates into their optical antipodes is based on chromatography on an optically active matrix. The compounds of the present invention may also be resolved by the formation of diastereomeric derivatives. Additional methods for the resolution of optical isomers known to those skilled in the art may be used. Such methods include those described by J. Jaques, A. Collet, and S. Wilen in "Enantiomers, Racemates, and Resolutions," John Wiley and Sons, New York (1981). Optically active compounds can be prepared from optically active starting materials or by the use of chiral catalysts. The absolute stereochemistry may be determined by methods known to those skilled in the art, such as vibrational circular dichroism (VCD) spectroscopy.
[0106] Furthermore, when double bonds or fully or partially saturated ring systems are present in a molecule, geometric isomers may be formed. It is intended that the separate geometric isomers, pure or partially purified geometric isomers, or mixtures thereof, are included within the scope of the present invention. Similarly, molecules with bonds that are restricted in rotation may form geometric isomers. These are also intended to be included within the scope of the present invention.
[0107] Furthermore, some of the compounds of the present invention may exist in different tautomeric forms, and it is intended that any tautomeric form that the compounds are able to form is included within the scope of the invention.
[0108] The present invention also includes isotopically labeled compounds similar to those claimed in Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), or (If), or pharmaceutically acceptable salts thereof, in which one or more atoms are represented by an atom of the same element having an atomic mass or mass number different from the atomic mass or mass number usually found in nature (e.g., 2 H, 3 H, 11 C. 13 C. 15 N, 18 F, etc.). 2 Particular mention is made of H-substituted compounds, ie compounds in which one or more H atoms are represented by deuterium.
[0109] In one embodiment of the present invention, one or more of the hydrogen atoms of a compound of formula (I), (Ia), (Ib), (Ic), (Id), (Ie), or (If) or a pharmaceutically acceptable salt thereof are represented by deuterium. It is recognized that elements exist in natural isotopic abundance in most synthetic compounds, resulting in the intrinsic incorporation of deuterium. However, the natural isotopic abundance of hydrogen isotopes such as deuterium is insignificant (approximately 0.015%) compared to the degree of stable isotopic substitution of the compounds presented herein. Thus, as used herein, designating an atom as deuterium at a position indicates that the abundance of deuterium is significantly greater than the natural abundance of deuterium. An atom not designated as a specific isotope is intended to represent any stable isotope of that atom, as would be apparent to one of ordinary skill in the art.
[0110] Pharmaceutical Composition The compound or pharmaceutically acceptable salt may be present in the composition as the sole active ingredient or in combination with other active ingredients. In addition, one or more pharmaceutically acceptable carriers or diluents may be present in the composition.
[0111] The pharmaceutical compositions may be specially formulated for administration by any suitable route, such as oral, rectal, nasal, pulmonary, topical (including buccal and sublingual), transdermal, intracisternal, intraperitoneal, vaginal, and parenteral (including subcutaneous, intramuscular, intrathecal, intravenous, and intradermal) routes, with the oral route being preferred. It will be understood that the preferred route will depend on the general condition and age of the subject being treated, the nature of the condition being treated, and the active ingredient selected.
[0112] Pharmaceutical compositions for oral administration include solid dosage forms such as capsules, tablets, dragees, pills, lozenges, powders and granules, which may be prepared with coatings, if appropriate.
[0113] Liquid dosage forms for oral administration include solutions, emulsions, suspensions, syrups, and elixirs.
[0114] Pharmaceutical compositions for parenteral administration include sterile aqueous and non-aqueous injectable solutions, dispersions, suspensions or emulsions as well as sterile powders to be reconstituted with sterile injectable solutions or dispersions before use.
[0115] Other suitable administration forms include suppositories, sprays, ointments, creams, gels, inhalants, skin patches, implants, and the like.
[0116] Conveniently, the compound of formula (I), (Ia), (Ib), (Ic), (Id), (Ie), or (If) is administered in a unit dosage form containing the compound in an amount of about 0.1 to 500 mg, such as 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg 100 mg, 150 mg, 200 mg, or 250 mg of a compound of the invention.
[0117] For parenteral administration, sterile aqueous solutions of compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), or (If) in aqueous propylene glycol may be employed. Such aqueous solutions should be suitably buffered, if necessary, and the liquid diluent should first be rendered isotonic with sufficient saline or glucose. The aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous, and intraperitoneal administration. The sterile aqueous vehicles employed are all readily available by standard techniques known to those skilled in the art. The aqueous solutions should be suitably buffered, if necessary, and the liquid diluent should first be rendered isotonic with sufficient saline or glucose. The aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous, and intraperitoneal administration. The sterile aqueous vehicles employed are all readily available by standard techniques known to those skilled in the art.
[0118] Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solutions, and various organic solvents. Lactose, terra alba, sucrose, cyclodextrin, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid, and lower alkyl ethers of cellulose. Examples of liquid carriers are syrup, peanut oil, olive oil, phosphorescent lipids, polyoxyethylene, and water. The pharmaceutical composition formed by combining a compound of formula (I), (Ia), (Ib), (Ic), (Id), (Ie), or (If) or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable carrier can be easily administered in a variety of dosage forms suitable for the administration route disclosed below.
[0119] Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules or tablets, each containing a predetermined amount of the active ingredient, which may include a suitable excipient. Further, the orally available formulation may be in the form of a powder or granules, a solution or suspension in an aqueous or non-aqueous liquid, or an oil-in-water or water-in-oil liquid emulsion.
[0120] If a solid carrier is used for oral administration, the preparation may be, for example, a powder in a hard gelatin capsule, or in tablet form, such as in pellet form, or in the form of a troche or lozenge. The amount of solid carrier may vary but will usually be from about 25 mg to about 1 g.
[0121] If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
[0122] Tablets may be prepared by mixing the active ingredient with conventional adjuvants and / or diluents, followed by compressing the mixture in a conventional tablet machine. Examples of adjuvants or diluents include corn starch, potato starch, talc, magnesium stearate, gelatin, lactose, gums, etc. Any other auxiliary or additive normally used for purposes such as coloring agents, flavoring agents, preservatives, etc. may also be used, provided that they are compatible with the active ingredients.
[0123] Conditions being treated The compounds of the present invention are intended for the treatment of diseases and disorders associated with modulation of endocannabinoid signaling activity, in which MAGL inhibitors may be therapeutically beneficial. As noted above, the compounds of the present invention may be beneficial in indications whose pathological characteristics include excessive neurotransmission, neuroinflammation, or neurodegeneration. Thus, in one embodiment, there is provided a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), or (If), or a pharmaceutically acceptable salt thereof, for use in the treatment of a disorder or disease selected from the group consisting of pain, epilepsy / seizure disorders, Alzheimer's disease, Huntington's chorea, Huntington's disease, multiple sclerosis, obsessive-compulsive disorder, Parkinson's disease, depression, post-traumatic stress disorder, generalized anxiety disorder, and dystonia.
[0124] Symptomatic treatment of multiple sclerosis Nearly all MS patients, of all subtypes, experience one or more symptoms: spasticity, pain, sleep disturbances, bladder dysfunction, and fatigue. Disease-modifying therapies do not improve symptoms. Spasticity affects over 80% of MS patients; 34% have moderate, severe, or complete spasticity. Severe spasticity is associated with increased costs and levels of care, and is independently associated with quality of life in MS. Two recent reviews support the use of exogenous cannabinoids for the treatment of spasticity and pain in MS (Whiting et al., JAMA. 2015); (Hill et al., JAMA. 2015).
[0125] Exogenous cannabinoid preparations are approved treatments for spasticity associated with MS. Sativex, an oromucosal spray mixture of the CB1 agonist THC and cannabidiol, another cannabis-derived alcohol, has been shown to reduce self-reported spasticity-related symptoms. A pivotal trial of Sativex using a randomized withdrawal design showed improvements with continued use of Sativex in spasticity frequency, sleep disturbance due to spasticity, subject's global impression of change, caregiver's global impression of change, and physician's global impression of change. Other clinical trials have demonstrated the activity of various exogenous cannabinoids in MS spasticity (Zajicek et al., Lancet. 2003; Collin et al., Eur J Neurol. 2007; Collin et al., Neurol Res. 2010). These parallel-group studies illustrate clinical trial designs and endpoints that could be used to demonstrate the benefit of MAGL inhibitors for MS spasticity.
[0126] In one embodiment, there is provided a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), or (If) or a pharmaceutically acceptable salt thereof for use in the treatment of multiple sclerosis.
[0127] In one embodiment, there is provided a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), or (If) or a pharmaceutically acceptable salt thereof for use in treating one or more symptoms in multiple sclerosis selected from fatigue, spasticity, depression, behavioral disturbances, irritability-agitation, and pain.
[0128] MAGL inhibitors are also believed to be beneficial in the treatment of indications related to autoimmune encephalomyelitis. Accordingly, in a further embodiment, there is provided a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), or (If), or a pharmaceutically acceptable salt thereof, for use in the treatment of Rasmussen's encephalitis, systemic lupus erythematosus, Behcet's disease, Hashimoto's encephalopathy, and Sydenham's chorea.
[0129] Amyotrophic lateral sclerosis Pryce et al. Handb Exp Pharmacol. 2015;231:213-31 describes how patients with amyotrophic lateral sclerosis (ALS) typically experience progressively worsening muscle weakness and / or fasciculations, bulbar symptoms, and eventually respiratory distress. Preclinical models of ALS suggest that cannabinoids may have significant neuroprotective effects.
[0130] Thus, in one embodiment, there is provided a compound of formula (I), (Ia), (Ib), (Ic), (Id), (Ie), or (If), or a pharmaceutically acceptable salt thereof, for use in the treatment of amyotrophic lateral sclerosis.
[0131] central pain Central pain is neuropathic pain resulting from lesions or dysfunction of the central nervous system, such as those associated with post-stroke, multiple sclerosis, neuromyelitis optica, idiopathic inflammatory transverse myelitis, spinal cord injury, humeroradial pain syndrome, and central craniofacial pain. Exogenous cannabinoids have demonstrated activity in the central pain associated with multiple sclerosis. A 4-week, randomized, double-blind, placebo-controlled, parallel-group study of an oral spray containing the CB1 agonist delta-9-tetrahydrocannabinol and cannabidiol (another cannabis-derived alcohol), THC / CBD, in MS and central pain showed that the active agent was superior to placebo in reducing mean pain intensity (NRS-11) and sleep disturbances (Rog et al., Neurology. 2005). The same THC / CBD formulation was studied in a larger group of MS patients with central neuropathic pain using a two-stage design; in the second phase of this study, time to treatment failure (the primary endpoint) statistically favored THC / CBD, as did improvements in pain NRS-11 and sleep quality (Langford et al., J Neurol. 2013). Furthermore, nabilone, a synthetic CB1 agonist structurally related to THC, demonstrated efficacy in MS-induced central neuropathic pain (Turcotte et al., Pain Med. 2015). Studies of exogenous cannabinoids in central pain have suggested activity, suggesting that MAGL inhibitors may also be effective in treating central pain. Thus, in one embodiment, a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), or (If) or a pharmaceutically acceptable salt thereof is provided for use in the treatment of central pain.
[0132] fibromyalgia Fibromyalgia (FM) is a common, chronic, idiopathic condition characterized by diffuse somatic pain and the presence of pressure allodynia. Duloxetine and pregabalin are specifically labeled for the treatment of FM pain, and tricyclic antidepressants such as amitriptyline, while not specifically labeled for the treatment of FM, are first-line treatments. There is no clear understanding of the pathology of FM, nor are there any validated preclinical models. However, studies of exogenous cannabinoids in FM have shown activity, suggesting that MAGL inhibitors may also have efficacy in the treatment of FM. Measures of pain (e.g., NRS-11, pain VAS) and the Fibromyalgia Impact Questionnaire (FIQ), which measures limitations in some activities of daily living affected by FM, have demonstrated drug activity in clinical trials for FM (Burckhardt et al., The fibromyalgia impact questionnaire: development and validation, J Rheumatol. 1991, 728-33; Mease et al., The Journal of Rheumatology January 2008, 35(1)20-30). A survey of Spanish FM patients, both cannabis users and non-users, identified the effects of cannabis on a range of disease symptoms, including pain, stiffness, well-being, relaxation, and sleepiness; perceived relief of pain, sleep disturbance, stiffness, mood disturbance, and anxiety were common (Fiz, PLoS One, 2011, 6(4), e18440). In an 8-week study of 40 patients, the exogenous cannabinoid nabilone improved pain as measured on a 10-cm visual analog scale, and improved the anxiety FIQ domain and FIQ total score compared with placebo (Skrabek et al., J Pain. 2008). In a study of 31 patients, nabilone improved sleep indices (Insomnia Severity Index) and was judged non-inferior to amitriptyline on pain measures (McGill Pain Questionnaire) and the FIQ (Ware, Anesth Analg, 2010, 110(2), 604-10).Thus, in one embodiment, there is provided a compound of formula (I), (Ia), (Ib), (Ic), (Id), (Ie), or (If), or a pharmaceutically acceptable salt thereof, for use in the treatment of fibromyalgia.
[0133] Migraine Migraine is a common episodic disorder characterized by pain in the head and face. Migraine attacks can be acutely treated with NSAIDs, acetaminophen, various triptans (e.g., sumatriptan), and antiemetics; however, some migraine patients experience pain that does not respond to existing treatment options. Data suggest that the endocannabinoid pathway may be involved in migraine. In patients with chronic migraine and likely analgesic overuse headache, CSF samples showed higher levels of the endocannabinoid palmitoylethanolamide and lower levels of anandamide compared with healthy controls (Sarchielli et al., Neuropsychopharmacology. 2007). Furthermore, a retrospective chart review of patients attending a medical marijuana clinic with a primary diagnosis of migraine found a decrease in migraine frequency after initiating marijuana therapy (Rhyne et al., Pharmacotherapy. 2016), suggesting that MAGL inhibitors may also be effective in treating migraine. Thus, in one embodiment, there is provided a compound of formula (I), (Ia), (Ib), (Ic), (Id), (Ie), or (If), or a pharmaceutically acceptable salt thereof, for use in the treatment of migraine.
[0134] In a further embodiment, disclosed herein is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), or (If) or a pharmaceutically acceptable salt thereof for use in the treatment or prevention of chronic migraine, the acute treatment of migraine and hemiplegic migraine.
[0135] Mood and anxiety disorders Mood and anxiety disorders are chronic conditions that impose costs on both patients and society. In relation to mood and anxiety disorders, the endocannabinoid system has received increasing attention in recent years. A recent study by Bedse G et al., Transl Psychiatry. 2018, suggested that the use of MAGL inhibitors may have beneficial effects on stress-related psychopathology. Thus, in one embodiment disclosed herein, a compound of formula (I), (Ia), (Ib), (Ic), (Id), (Ie), or (If) or a pharmaceutically acceptable salt thereof is provided for use in the treatment of mood and anxiety disorders.
[0136] In a further embodiment disclosed herein, there is provided a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), or (If) or a pharmaceutically acceptable salt thereof for use in the treatment of a mood and anxiety disorder selected from depression and GAD.
[0137] In further embodiments disclosed herein, there is provided a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), or (If) or a pharmaceutically acceptable salt thereof for use in the treatment of depression selected from major depressive disorder, treatment-resistant depression, catatonic depression, melancholic depression, atypical depression, psychotic depression, perinatal depression, postpartum depression, bipolar depression, including bipolar I depression and bipolar II depression, and mild, moderate, or severe depression. In further embodiments disclosed herein, there is provided a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), or (If) or a pharmaceutically acceptable salt thereof for use in the treatment of major depressive disorder.
[0138] In further embodiments disclosed herein, there is provided a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), or (If), or a pharmaceutically acceptable salt thereof, for use in the treatment of GAD.
[0139] Post-traumatic stress disorder Post-traumatic stress disorder (PTSD) is a trauma- or stress-related disorder. Patients with PTSD experience symptoms of traumatic flashbacks, avoidance, hyperarousal, and negative cognition / mood. A review by Hill et al., Neuropsychopharmacology 2018, suggested that drugs that affect endocannabinoid signaling (such as MAGL inhibitors) may be beneficial in treating PTSD symptoms. Thus, in one embodiment disclosed herein, a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), or (If) or a pharmaceutically acceptable salt thereof is provided for use in treating PTSD.
[0140] Some embodiments disclosed herein are methods of modulating the activity of MAGL. Contemplated methods include, for example, exposing the enzyme to a compound described herein. The ability of a compound described herein to modulate or inhibit MAGL is assessed by procedures known in the art and / or described herein. Another aspect of the disclosure provides a method of treating a disease associated with MAGL expression or activity in a patient.
[0141] epilepsy A study by Sugaya et al., Cell Rep. 2016, suggests that 2-AG is crucial for the suppression of epileptic seizures. Thus, in another embodiment, a compound of formula (I), (Ia), (Ib), (Ic), (Id), (Ie), or (If) is used in the treatment of epilepsy / seizure disorders.
[0142] In one embodiment, a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), or (If) is used in the treatment of an epilepsy / seizure disorder selected from acute recurrent seizures, temporal lobe epilepsy, Dravet syndrome, Lennox-Gastaut syndrome, or Angelman syndrome.
[0143] Combination therapy Combination therapy is also contemplated herein, e.g., co-administration of a compound of the present invention with an additional active agent as part of a specific treatment regimen intended to provide a beneficial effect from the interaction of these therapeutic agents. Beneficial effects of the combination include, but are not limited to, pharmacokinetic or pharmacodynamic interactions resulting from the combination of therapeutic agents. Administration of these combined therapeutic agents typically occurs over a defined period of time (usually weeks, months, or years, depending on the combination selected). Combination therapy is intended to encompass sequential administration of multiple therapeutic agents, i.e., administration of each therapeutic agent at different times, as well as administration of at least two of these therapeutic agents or therapeutic agents substantially simultaneously.
[0144] Substantially simultaneous administration can be achieved, for example, by administering to the subject a single formulation or composition (e.g., a tablet or capsule) having a fixed ratio of each therapeutic agent, or by administering multiple single formulations (e.g., capsules) for each of the therapeutic agents. The sequential or substantially simultaneous administration of each therapeutic agent can be effected by any suitable route, including, but not limited to, oral, intravenous, intramuscular, and direct absorption through mucosal tissue. The therapeutic agents can be administered by the same route or by different routes. For example, a first therapeutic agent of a selected combination can be administered by intravenous injection and the other therapeutic agent of the combination can be administered orally. Alternatively, for example, all therapeutic agents can be administered orally, or all therapeutic agents can be administered by intravenous injection.
[0145] Combination therapy also encompasses administering the above-mentioned therapeutic agents in further combination with other bioactive ingredients and non-drug therapies. When combination therapy further includes a non-drug therapy, the non-drug therapy can be administered at any appropriate time, as long as a beneficial effect is achieved through the interaction of the combined therapeutic agent and non-drug therapy. For example, in appropriate cases, the beneficial effect can still be achieved even if radiation therapy is separated in time from the administration of the therapeutic agent, perhaps by days or weeks.
[0146] The components of the combination are administered to a patient simultaneously or sequentially. It will be understood that the components may be present in the same pharmaceutically acceptable carrier and thus be administered simultaneously. Alternatively, the active ingredients may be present in separate pharmaceutical carriers, such as conventional oral dosage forms, which are administered simultaneously or sequentially.
[0147] For example, for the contemplated treatment of pain, the disclosed compounds are co-administered with another therapeutic agent for pain, such as an opioid, a cannabinoid receptor (CB1 or CB2) modulator, a COX-2 inhibitor, acetaminophen, and / or a nonsteroidal anti-inflammatory agent. For example, additional therapeutic agents co-administered for the treatment of pain include morphine, pregabalin, gabapentin, codeine, hydromorphone, hydrocodone, oxymorphone, fentanyl, tramadol, and levorphanol.
[0148] Other contemplated therapeutic agents for co-administration include aspirin, naproxen, ibuprofen, salsalate, diflunisal, dexibuprofen, fenoprofen, ketoprofen, oxaprozin, loxoprofen, indomethacin, tolmetin, sulindac, etodolac, ketorolac, piroxicam, meloxicam, tenoxicam, droxicam, lornoxicam, celecoxib, parecoxib, rimonabant, and / or etoricoxib. [Example]
[0149] Experimental Section general synthesis Compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), and (If) or salts thereof may be prepared by synthetic processes. Schemes 1-3 and Examples 1-34 below are representative of methods useful for synthesizing one or more compounds according to Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), and (If). Schemes 1-3 provided are not intended to limit the scope of the invention in any way.
[0150] Scheme 1 [ka] As shown in Scheme 1, 6-(tert-butoxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid (II) may be reacted with a primary amine (R may be heteroaryl or heterocyclic) in the presence of a suitable base and solvent (e.g., DIPEA and THF) to form intermediates of type III. Alternatively, intermediates of type II may be subjected to an acid halide reagent prior to step i) to form an acid halide. The amide-forming step i) followed by deprotection in step ii) carried out in a suitable acid and solvent (e.g., TFA and DCM) provides intermediates of type IV. The deprotection step is followed by a coupling reaction in step iii) comprising the reaction of intermediates of type IV with 1,1,1,3,3,3-hexafluoropropan-2-ol in the presence of a coupling agent such as CDI in a suitable solvent (e.g., MeCN) to provide compounds of the present invention.
[0151] Scheme 2 [ka] An alternative synthesis provides compounds in which the amide linker is a tertiary amine (R may be heteroaryl or heterocycle). As seen in Scheme 2, intermediates of type III are subjected to alkylation in step ia) to form intermediates of type IIIa. Intermediates of type IIIa may subsequently be subjected to deprotection step ii) and coupling step iii) as described in Scheme 1 to provide compounds of the invention.
[0152] Scheme 3 [ka] As shown in Scheme 3, some compounds of the present invention may be prepared by starting with commercially available t-butyl 1-carbamoyl-6-azaspiro[2.5]octane-6-carboxylate and subjecting it to an aryl halide or heteroaryl halide (X is halogen; R is heteroaryl or phenyl) to form intermediates of type VI. The remainder of the synthesis (steps ii) and iii)) continues as shown in Scheme 1.
[0153] List of abbreviations As used above, and throughout the description of the present invention, the following abbreviations, unless otherwise indicated, shall be understood to have the following meanings: ACN or MeCN acetonitrile Bn Benzyl BOC or Boc tert-butyl carbamate CDI 1,1'-carbonyldiimidazole Cy Cyclohexyl DCE Dichloroethane (ClCH2CH2Cl) DCM dichloromethane (CH2Cl2) DIPEA or DIEA Diisopropylethylamine DMAP 4-(N,N-dimethylamino)pyridine DMF Dimethylformamide DMA N,N-dimethylacetamide DMSO dimethyl sulfoxide equiv equivalent Et Ethyl EtOH ethanol EtOAc ethyl acetate HATU 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate HPLC High-Performance Liquid Chromatography LAH Lithium Aluminum Hydride Me methyl MeOH Methanol MS mass spectrometry NMM N-methylmorpholine NMR nuclear magnetic resonance PMB para-methoxybenzyl TEA Triethylamine TFA trifluoroacetic acid THF tetrahydrofuran TLC thin layer chromatography
[0154] I. Chemical synthesis Unless otherwise noted, reagents and solvents were used as received from commercial suppliers. Anhydrous solvents and oven-dried glassware were used for moisture- and / or oxygen-sensitive synthetic transformations. Yields were not optimized. Reaction times are approximate and not optimized. Column chromatography and thin-layer chromatography (TLC) were performed on silica gel unless otherwise noted. Spectra are given in ppm (δ) and coupling constants (J) are reported in Hertz. For proton spectra, the solvent peak was used as the reference peak.
[0155] Analysis method LC-MS method The analytical LC-MS system was equipped with a Shimadzu LCMS-2020, a PDA detector (operating at 254 nm), an ELSD detector, and an ESI source operating in positive ion mode. LC conditions: Method A: Column: Kinetex EVO C18 50 * 3.0 mm, 2.6 μm, and operated at 40° C. with a 1.2 mL / min binary gradient consisting of water + 5 mM NH4HCO3 (A) and ACN (B). R ) is based on a UV trace at 254 nm and is expressed in minutes. Gradient: 10% B in 0.01 min 95%B in 2.00 2.70 min 95%B 2.75 min 10% B Total running time: 3.00 minutes
[0156] Method B: Column: Kinetex EVO C18 50* 3.0 mm, 2.6 μm, and operated at 40° C. with a 1.2 mL / min binary gradient consisting of water + 5 mM NH4HCO3 and ACN (B). R ) is based on a UV trace at 254 nm and is expressed in minutes. Gradient: 10% B in 0.01 min 3. 60%B for 20 minutes 95%B in 4.00 4.80% 95%B 4. 10% B in 90 Total running time: 5.00 minutes
[0157] Method C: Column: Express C18 50 * 3.0 mm and operated at 40° C. with a 1.5 mL / min binary gradient consisting of water + 0.05% TFA (A) and ACN + 0.05% TFA (B). R ) is based on a UV trace at 254 nm and is expressed in minutes. Gradient: 20% B in 0.01 min 3.50% B 4.30 min 95%B 95%B in 4.00 5. 5%B for 10 min Total running time: 5.30 minutes
[0158] Method D: Column: HALO C18 30 * 3.0 mm, 2 μm, operated at 40° C. with a 1.5 mL / min binary gradient consisting of water + 0.05% TFA (A) and ACN + 0.05% TFA (B). R ) is based on the UV trace at 200 nm and is expressed in minutes. Gradient: 5% B in 0.01 min 1.20 min 100% B 1.80% 100% B 1.82 min 5%B Total execution time: 2.0 minutes
[0159] Method E: Column: Poroshell HPH-C18 50 *3.0 mm, 2.7 μm, and operated at 40° C. with a 1.2 mL / min binary gradient consisting of water + 6.5 mM NH4HCO3 + ammonia (pH = 10) (A) and ACN (B). R ) is based on a UV trace at 254 nm and is expressed in minutes. Gradient: 10% B in 0.01 min 95%B in 2.00 2.70 min 95%B 2.75 min 10% B Total running time: 3.00 minutes
[0160] Method F: Column: Express C18 50 * 3.0 mm and operated at 40° C. with a 1.5 mL / min binary gradient consisting of water + 0.05% TFA (A) and ACN + 0.05% TFA (B). R ) is based on a UV trace at 254 nm and is expressed in minutes. Gradient: 5% B in 0.01 min 95%B in 2.00 2.70 min 95%B 2.80 min 5%B Total execution time: 3.0 minutes
[0161] Method G: Column: Kinetex EVO C18 50 * 3.0 mm, 2.6 μm, and operated at 40° C. with a 1.2 mL / min binary gradient consisting of water + 5 mM NH4HCO3 and ACN (B). R ) is based on a UV trace at 254 nm and is expressed in minutes. Gradient: 30% B in 0.01 min 3. 70% B for 20 minutes 95%B in 4.00 4.80% 95%B 4. 10% B in 90 Total running time: 5.00 minutes
[0162] Method H: Column: Poroshell HPH-C18 50 *3.0 mm, 2.7 μm, operated at 40° C. with a 1.2 mL / min binary gradient consisting of water + 5 mM NH4HCO3 (A) and acetonitrile (B). R ) is based on a UV trace at 254 nm and is expressed in minutes. Gradient: 10% B in 0.01 min 3. 60%B for 20 minutes 95%B in 4.00 4.80% 95%B 4. 10% B in 90 Total running time: 5.00 minutes
[0163] Method I: Column: CORTECS C18 50 * 2.1 mm, 2.7 μm, and operated at 40° C. with a 1.5 mL / min binary gradient consisting of water + 0.05% trifluoroacetic acid (A) and acetonitrile + 0.05% trifluoroacetic acid (B). R ) is based on a UV trace at 254 nm and is expressed in minutes. Gradient: 5% B in 0.01 min 100%B in 2.00 2.80% 100% B 2.90 min 5%B Total running time: 3.00 minutes
[0164] Method J: Column: CORTECS C18 50 * 2.1 mm, 2.7 μm, and operated at 40° C. with a 1.0 mL / min binary gradient consisting of water + 0.05% trifluoroacetic acid (A) and acetonitrile + 0.05% trifluoroacetic acid (B). R ) is based on a UV trace at 254 nm and is expressed in minutes. Gradient: 5% B in 0.01 min 3. 60%B for 20 minutes 4. 95%B in 10 min 95%B in 5.00 5. 5%B for 10 min Total running time: 5.30 minutes
[0165] Method K: Column: Express C18 50 * 3.0 mm and operated at 40° C. with a 1.5 mL / min binary gradient consisting of water + 0.05% TFA (A) and ACN + 0.05% TFA (B). R ) is based on a UV trace at 254 nm and is expressed in minutes. Gradient: 30% B in 0.01 min 3.50 min 60%B 4.30 min 95%B 95%B in 4.00 5. 5%B for 10 min Total running time: 5.30 minutes
[0166] Method L: Column: Kinetex EVO C18 50 * 3.0 mm, 2.6 μm, and operated at 40° C. with a 1.2 mL / min binary gradient consisting of water + 5 mM NH4HCO3 and ACN (B). R ) is based on a UV trace at 254 nm and is expressed in minutes. Gradient: 30% B in 0.01 min 3. 50% B for 20 minutes 95%B in 4.00 4.80% 95%B 4. 10% B in 90 Total running time: 5.00 minutes
[0167] Method M: Column: Poroshell HPH-C18 50 * 3.0 mm, 2.7 μm, and operated at 40° C. with a 1.2 mL / min binary gradient consisting of water + 6.5 mM NH4HCO3 + ammonia (pH = 10) (A) and ACN (B). R ) is based on a UV trace at 254 nm and is expressed in minutes. Gradient: 10% B in 0.01 min 60%B in 3.00 95%B in 4.00 4.70 min 95%B 4. 10% B in 90 Total running time: 5.00 minutes
[0168] Method N: Column: Kinelex XB-C18 50 * 3.0 mm, 2.6 μm, operated at 45° C. with a 1.5 mL / min binary gradient consisting of water + 0.05% TFA (A) and CHCl + 0.05% TFA (B). R ) is based on a UV trace at 254 nm and is expressed in minutes. Gradient: 5% B in 0.01 min 50%B for 3.00 100%B in 4.00 4. 100% B for 60 minutes 4.70 min 5%B Total running time: 5.20 minutes
[0169] Method 0: Column HALOC18 30 * 3.0 mm, 2 μm, operated at 40° C. with a 1.5 mL / min binary gradient consisting of water + 0.05% TFA (A) and ACN + 0.05% TFA (B). R ) is based on the UV trace at 200 nm and is expressed in minutes. Gradient: 100% B in 2.20 min 2.70 min 100% B 2.72 min 5%B Total execution time: 3.0 minutes
[0170] Method P: The column is an Express C18 50 mm, operated at 40° C. with a 1.5 mL / min binary gradient consisting of water + 0.05% TFA (A) and ACN + 0.05% TFA (B). Retention time (t R ) is based on a UV trace at 254 nm and is expressed in minutes. Gradient: 2% B in 0.01 100%B in 2.00 2.70 min 100% B 2.75%B Total execution time: 3.0 minutes
[0171] 1 H NMR method 1H NMR spectra were recorded on a Bruker Avance HD at 300 or 400 MHz. Chemical shift values are expressed in ppm relative to tetramethylsilane. The following abbreviations or combinations thereof are used for the multiplicity of NMR signals: br = broad line, d = doublet, dd = doublet of doublets, dt - doublet of triplets, hept = septet, m = multiplet, q = quartet, quint = quintet, s = singlet, t = triplet, td = triplet of doublets.
[0172] Example 1: 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] Step 1: Synthesis of t-butyl 1-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] A vial was charged with 6-(t-butoxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid (255 mg) (Nantong MYBio-pharm. Co., Ltd.), DMF (10 mg), and DCM (10 mL). Oxalyl chloride (189 mg) was added dropwise at 0 °C. The resulting solution was stirred at 0 °C for 2 hours and concentrated under reduced pressure to give t-butyl 1-(chlorocarbonyl)-6-azaspiro[2.5]octane-6-carboxylate. A separate vial was charged with pyridin-3-amine (94.0 mg), THF (5 mL), and DIPEA (258 mg). t-Butyl 1-(chlorocarbonyl)-6-azaspiro[2.5]octane-6-carboxylate in THF (5 mL) was added dropwise at 0 °C. The resulting solution was stirred at room temperature overnight and quenched by the addition of water (10 mL). The mixture was extracted with EtOAc (3 × 10 mL), and the combined organic layers were washed with brine (3 × 10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was chromatographed on a silica gel column using EtOAc / petroleum ether (2 / 1) to give t-butyl 1-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (160 mg). LCMS (ESI, m / z): 332 [M+H] + .
[0173] Step 2: Synthesis of N-(pyridin-3-yl)-6-azaspiro[2.5]octane-1-carboxamide [ka] A vial was charged with t-butyl 1-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (160 mg), DCM (5 mL), and TFA (5 mL). The resulting solution was stirred at room temperature for 2 hours and concentrated under reduced pressure. The crude product was dissolved in water (10 mL). The pH value of the solution was adjusted to 8 with saturated sodium bicarbonate solution. The mixture was extracted with DCM (3 × 10 mL), and the combined organic layers were washed with brine (2 × 10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give N-(pyridin-3-yl)-6-azaspiro[2.5]octane-1-carboxamide (112 mg). LCMS (ESI, m / z): 232 [M+H] + .
[0174] Step 3: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl(±)1-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] A vial was charged with 1,1,1,3,3,3-hexafluoropropan-2-ol (489 mg), ACN (5 mL), 1,1'-carbonyldiimidazole (94.0 mg), and N-(pyridin-3-yl)-6-azaspiro[2.5]octane-1-carboxamide (112 mg). The resulting solution was stirred at 80°C overnight and quenched by the addition of water (10 mL). The mixture was extracted with EtOAc (3 x 10 mL), and the combined organic layers were washed with brine (3 x 10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude material was purified by preparative HPLC using the following gradient conditions: 40% ACN / 60% ACN in 7 min to 70% ACN, then increasing to 100% ACN in 0.1 min, holding at 100% ACN for 1.9 min, then decreasing to 40% ACN in 0.1 min, holding at 40% for 1.9 min on a Waters 2767-5 chromatograph. Column: X-bridge Prep C18, 19 *150 mm 5 μm; Mobile phase: Phase A: aqueous NH4HCO3 (0.05%); Phase B: ACN; Detector, UV 220 and 254 nm. Purification yielded 32.7 mg of 1,1,1,3,3,3-hexafluoropropan-2-yl(±)1-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate. 1 H NMR(300MHz,chloroform-d)δ 8.57(br,1H),8.40-8.32(m,2H),8.17(d,J=7.8Hz,1H),7.30-7.29(m,1H),5.86-5.69(m,1H),3.72-3.49(m ,4H),1.97-1.84(m,2H),1.62-1.54(m,2H),1.46-1.39(m,2H),1.03-0.95(m,1H).LCMS(ESI,m / z):426[M+H] + .
[0175] Example 2: 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate and Example 3: 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] The racemic mixture (32.7 mg) prepared in Example 1 was separated using preparative chiral HPLC (column: CHIRALPAK IG, 2 * The two enantiomers were separated by HPLC (25 cm, 5 μm; mobile phase A: Hex (0.1% DEA)--HPLC, mobile phase B: EtOH-HPLC; flow rate: 20 mL / min; gradient: 5% B to 5% B in 17 min; UV 220 / 254 nm) to give:
[0176] Example 2 9.0 mg of 1,1,1,3,3,3-hexafluoropropan-2-yl(S)-1-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate. 1 H NMR(400MHz,chloroform-d)δ 8.79(br,1H),8.49(br,1H),8.24(br,1H),8.01(s,1H),7.33(br,1H),5.77(br,1H),3.73-3.63(m, 1H),3.59-3.39(m,3H),1.96(br,2H),1.87-1.59(m,2H),1.48(br,1H),1.40(s,1H),1.04(s,1H).t R =11.695 minutes. LCMS (Method A) (ESI, m / z): 426[M+H] + . and the corresponding enantiomers
[0177] Example 3 9.8 mg of 1,1,1,3,3,3-hexafluoropropan-2-yl (R)-1-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate. 1 H NMR(400MHz,chloroform-d)δ 8.72(br,1H),8.35(br,1H),8.22(br,1H),8.04(s,1H),7.32(br,1H),5.87(br,1H),3.80-3.70(m, 1H),3.73-3.41(m,3H),1.87(br,2H),1.63-1.59(m,2H),1.48(br,1H),1.40(s,1H),1.04(s,1H).t R =14.452 min.LCMS(Method B)(ESI,m / z):426[M+H] + .
[0178] Determination of absolute configuration of Examples 2 and 3 The absolute configuration of Example 3 was determined using vibrational circular dichroism (VCD) (Appl. Spectrosc. 65(7), 699(2011)). Spectra were acquired on a Chiral® equipped with a DualPEM VCD spectrometer and compared to calculations (DFT calculation methodology and standard set = B3LYP / 6311Gdp using CPCM (chloroform)). Analysis of the VCD spectrum of Example 3 against the VCD spectrum calculated for the (R)-enantiomer establishes Example 3 as the (R)-enantiomer and therefore Example 2 as the (S)-enantiomer. These samples were analyzed by chiral HPLC under the following conditions: Column: CHIRALPAK IC, 3.0 * 100 mm, 3 μm; Mobile phase: A phase: CO2, B phase: IPA (0.1% DEA); Flow rate: 2 mL / min; Gradient: 10% to 50% in 2.0 min, hold at 50% for 1.0 min; Detection: 220 nm. Example 2: First eluting enantiomer (t R =0.944 minutes) Example 3: Second eluting enantiomer (t R =1.154 minutes)
[0179] Preparation of intermediates of known absolute configuration: synthesis Armed with this information, the building blocks Intermediate 2A and Intermediate 3A were converted to Examples 2 and 3 as described below. The absolute configurations of the enantiomers were then determined by comparing the elution orders with the known Examples 2 and 3 described above. The details of the synthesis of Examples 2 and 3, which have known absolute configurations, are outlined below.
[0180] Step 1: Synthesis of 1-benzyl 6-(t-butyl) 6-azaspiro[2.5]octane-6-1,6-dicarboxate [ka] A solution of 6-(t-butoxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid (240 g) in acetone (5 L) was placed in a flask purged and maintained with an inert atmosphere of nitrogen. Benzyl bromide (170.6 g) and K2CO3 (259.8 g) were added. The resulting solution was refluxed for 2-3 hours. The reaction was then cooled to room temperature and filtered. The filter cake was washed with ethyl acetate. The combined filtrate was concentrated under vacuum to yield 297 g of crude 1-benzyl 6-(t-butyl)6-azaspiro[2.5]octane-1,6-dicarboxate.
[0181] Step 2: Synthesis of benzyl 6-azaspiro[2.5]octane-1-carboxylate hydrochloride [ka] A solution of crude 1-benzyl 6-(t-butyl) 6-azaspiro[2.5]octane-1,6-dicarboxate (297 g) in DCM (1.5 L) was placed in a flask purged and maintained with an inert atmosphere of nitrogen. HCl (g) in 1,4-dioxane (4 M, 1.5 L) was added dropwise. The resulting solution was stirred at room temperature for 1 h and concentrated in vacuo. The crude material was slurried with EtO (10 V) to give 198.3 g of benzyl 6-azaspiro[2.5]octane-1-carboxylate.
[0182] Step 3: Synthesis of 1-benzyl 6-(1,1,1,3,3,3-hexafluoropropan-2-yl) 6-azaspiro[2.5]octane-1,6-dicarboxate [ka] A solution of 1,1,1,3,3,3-hexafluoropropan-2-ol (393 g) in DCM (2 L) was placed in a flask purged and maintained with an inert atmosphere of nitrogen. The mixture was cooled to 0 °C, and triphosgene (106.9 g) was added batchwise. DIPEA (550 g) was then added dropwise at 0–10 °C. The mixture was stirred at this temperature for 1.5 h. Next, a solution of benzyl 6-azaspiro[2.5]octane-1-carboxylate hydrochloride (198 g) in DCM (2 L) was added dropwise at 0 °C. The resulting solution was stirred at room temperature for 2 h. The reaction mixture was quenched by pouring into water (6 L) and then extracted with DCM (2 × 2 L). The combined organic layers were washed with brine (1 × 3 L), dried over anhydrous sodium sulfate, and concentrated in vacuo. The residue was chromatographed on a silica gel column with EtOAc / petroleum ether (1 / 30) to give 265 g of 1-benzyl 6-(1,1,1,3,3,3-hexafluoropropan-2-yl) 6-azaspiro[2.5]octane-1,6-dicarboxate.
[0183] Step 4: Isolation of (S)-1-benzyl 6-(1,1,1,3,3,3-hexafluoropropan-2-yl) 6-azaspiro[2.5]octane-1,6-dicarboxate (Intermediate 2A) and (R)-1-benzyl 6-(1,1,1,3,3,3-hexafluoropropan-2-yl) 6-azaspiro[2.5]octane-1,6-dicarboxate (Intermediate 3A) [ka] The racemic mixture of 1-benzyl 6-(1,1,1,3,3,3-hexafluoropropan-2-yl) 6-azaspiro[2.5]octane-1,6-dicarboxate (265 g) prepared in step 3 was separated using preparative SFC-HPLC (column: CHIRALPAK IG-3 3.0 * 50 mm, 3 μm; mobile phase: A phase: CO2, B phase: MeOH (0.1% DEA); flow rate: 2 mL / min; gradient: 2% B; 220 nm) and the absolute configuration was determined after preparation of the final product (Example 2 and Example 3) and comparison of the elution order on a chiral column. Intermediate 2A: 110 g of (S)-1-benzyl 6-(1,1,1,3,3,3-hexafluoropropan-2-yl) 6-azaspiro[2.5]octane-1,6-dicarboxate. 1 H NMR(300MHz,chloroform-d)δ 7.46-7.28(m,5H),5.75(p,J=6.3Hz,1H),5.13(s,2H),3.57(m,3H),3.28(m,1H),1. 86-1.61(m,3H),1.56-1.36(m,2H),1.27-1.19(m,1H),0.99(dd,J=8.2,4.7Hz,1H).t R =1.572 minutes. LCMS (Method O) (ESI, m / z): 440[M+H] + and Intermediate 3A: 100 g of 1-benzyl 6-(1,1,1,3,3,3-hexafluoropropan-2-yl)(R)-6-azaspiro[2.5]octane-1,6-dicarboxate. 1 H NMR(300MHz,chloroform-d)δ 7.36(d,J=2.6Hz,5H),5.75(p,J=6.3Hz,1H),5.13(d,J=1.4Hz,2H),3.71-3.40(m,3H),3.39-3.13(m,1H), 1.71(ddd,J=29.4,9.4,5.2Hz,3H),1.57-1.36(m,2H),1.23(d,J=5.2Hz,1H),0.99(dd,J=8.1,4.7Hz,1H).t R =1.572 minutes. LCMS (Method O) (ESI, m / z): 440[M+H] + .
[0184] Step 5-1: Synthesis of (S)-6-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid (Intermediate 2B) [ka] A solution of 1-benzyl 6-(1,1,1,3,3,3-hexafluoropropan-2-yl)(S)-6-azaspiro[2.5]octane-1,6-dicarboxyl (110 g) in THF (2 L) was added to the flask. Wet Pd / C (22 g, 10% wt, 50% HO) was added to the mixture. The resulting mixture was purged and replaced with H three times, then stirred under H at room temperature for 3 h. The mixture was filtered, and the filter cake was washed with HF (2 × 500 mL). The combined filtrates were concentrated in vacuo, and the crude material was coevaporated with toluene (2 × 1 L) to give 90 g of crude (S)-6-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid. 0.2 g of the crude product was purified by silica column chromatography to obtain pure characterization data. 1 H NMR(300MHz,chloroform-d)δ 5.78(h,J=6.3Hz,1H),3.79-3.40(m,4H),1.85(q,J=6.1Hz,2H),1.65(dd,J=8.0,5.4Hz,1 H),1.54(dq,J=10.9,5.8,5.0Hz,2H),1.28(t,J=5.1Hz,1H),1.09(dd,J=8.1,4.8Hz,1H).t R =1.441 minutes. LCMS (Method O) (ESI, m / z): 350[M+H] + .
[0185] Step 6-1: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl(S)-1-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (Example 2) [ka] A reaction vial was charged with a solution of crude (S)-6-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid (50 mg) in DCM (1 mL). EDC·HCl (30 mg) and HOBt (39 mg) were added, and the resulting mixture was stirred for 15 min. Pyridin-3-amine (18 mg) and DIEA (37 mg) were added. The final reaction mixture was stirred overnight at room temperature. The mixture was diluted with HO (10 mL) and extracted with DCM (1 × 5 mL). The combined organic phase was dried over anhydrous NaSO and concentrated. The crude was purified by preparative HPLC to give 1,1,1,3,3,3-hexafluoropropan-2-yl(S)-1-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (35 mg). 1 H NMR(300MHz,chloroform-d)δ 8.59(s,1H),8.27(dd,J=41.0,6.5Hz,2H),7.96(s,1H),7.30(dd,J=8.4,4.7Hz,1H),5.76(dd,J=11.6,6.0Hz,1H),3. 79-3.35(m,4H),1.85(d,J=6.0Hz,2H),1.58(dd,J=8.0,5.3Hz,2H),1.51-1.35(m,2H),1.02(dd,J=8.1,4.7Hz,1H).t R =1.255 minutes. LCMS (Method O) (ESI, m / z): 426[M+H] + . CHIRALPAK IC, 3.0 * 100 mm, 3 μm; Mobile phase: A phase: CO2, B phase: IPA (0.1% DEA); Flow rate: 2 mL / min; Gradient: 10% to 50% in 2.0 min, hold at 50% for 1.0 min; Detection: 220 nm:t R =1.928 minutes.
[0186] Intermediate 2B was converted to Example 2, and the absolute configuration of Intermediate 2B was determined to be the (S)-enantiomer after comparing the elution order of Example 2 (prepared in Step 6-1) and Example 3 (prepared in Step 6-2) via chiral chromatography.
[0187] Step 5-2: Synthesis of (R)-6-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid (Intermediate 3B) [ka] A flask was charged with a solution of 1-benzyl 6-(1,1,1,3,3,3-hexafluoropropan-2-yl)(R)-6-azaspiro[2.5]octane-1,6-dicarboxate (1.9 g, 4.3 mmol, 1.0 equiv.) in THF (40 mL). Wet Pd / C (0.38 g, 10% wt, 50% HO) was added to the mixture. The resulting mixture was purged and flushed with H twice and stirred under H at room temperature for 2 h. The mixture was filtered, and the filter cake was washed with HF (2 × 50 mL). The combined filtrate was concentrated under vacuum to give 1.5 g of crude (R)-6-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid, which was used directly in the next step without further purification.
[0188] Step 6-2: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl (R)-1-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (Example 3) [ka] A reaction vial was charged with a solution of crude (R)-6-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid (50 mg) in DCM (1 mL). EDC·HCl (30 mg) and HOBt (39 mg) were added, and the resulting mixture was stirred for 15 min. Pyridin-3-amine (18 mg) and DIEA (37 mg) were added. The final reaction mixture was stirred overnight at room temperature. The mixture was diluted with HO (10 mL) and extracted with DCM (1 × 5 mL). The combined organic phase was dried over anhydrous NaSO, filtered, and concentrated. The crude was purified by preparative HPLC to give 1,1,1,3,3,3-hexafluoropropan-2-yl (R)-1-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (50 mg) as a white solid. 1 H NMR(300MHz,chloroform-d)δ 8.59(t,J=3.2Hz,1H),8.33(dd,J=4.8,1.4Hz,1H),8.17(d,J=8.6Hz,2H),7.32-7.26(m,1H),5.76(h,J=6.1Hz,1H),3.7 4-3.35(m,4H),1.86(t,J=6.0Hz,2H),1.59(dd,J=8.0,5.2Hz,2H),1.37(t,J=5.0Hz,2H),1.00(dd,J=8.0,4.6Hz,1H).t R =1.266 minutes. LCMS(ESI,m / z):426[M+H] + . CHIRALPAK IC, 3.0 * 100 mm, 3 μm; Mobile phase: A phase: CO2, B phase: IPA (0.1% DEA); Flow rate: 2 mL / min; Gradient: 10% to 50% in 2.0 min, hold at 50% for 1.0 min; Detection: 220 nm:t R =2.030 minutes.
[0189] After comparing the elution orders of Example 2 (prepared in Step 6-1) and Example 3 (prepared in Step 6-2) via chiral chromatography, the absolute configuration of Intermediate 3B was determined to be the (R)-enantiomer.
[0190] Intermediates 2B and 3B of known absolute configuration were used in the synthesis of Examples 5, 6, 8, and 9 below.
[0191] Example 4: 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] Step 1: Synthesis of t-butyl 1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] t-Butyl 1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate was prepared in a similar manner to Step 1 of Example 1 using 6-[(t-butoxy)carbonyl]-6-azaspiro[2.5]octane-1-carboxylic acid (600 mg), DMF (17.4 mg), oxalyl chloride (386 mg), pyridazin-3-amine (245 mg), and t-butyl 1-(chlorocarbonyl)-6-azaspiro[2.5]octane-6-carboxylate to give the title compound (360 mg). LCMS (ESI, m / z): 333 [M+H] + .
[0192] Step 2: Synthesis of N-(pyridazin-3-yl)-6-azaspiro[2.5]octane-1-carboxamide [ka] N-(pyridazin-3-yl)-6-azaspiro[2.5]octane-1-carboxamide was prepared using t-butyl 1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (180 mg) and TFA (5 mL) as described in Step 2 of Example 1 to give the title compound (125 mg). LCMS (ESI, m / z): 233 [M+H] + .
[0193] Step 3: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl 1-[(pyridazin-3-yl)carbamoyl]-6-azaspiro[2.5]octane-6-carboxylate [ka] 1,1,1,3,3,3-Hexafluoropropan-2-yl 1-[(pyridazin-3-yl)carbamoyl]-6-azaspiro[2.5]octane-6-carboxylate was prepared using N-(pyridazin-3-yl)-6-azaspiro[2.5]octane-1-carboxamide (125 mg), 1,1'-carbonyldiimidazole (105 mg), and 1,1,1,3,3,3-hexafluoropropan-2-ol (904 mg) as described in Step 3 of Example 1 to afford the title compound (33.0 mg).
[0194] Example 5: 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate and Example 6: 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] The racemic mixture (33.0 mg) prepared in Example 4 was separated by preparative chiral HPLC (column: CHIRALPAK IC, 2* The two enantiomers were separated by a 25 cm, 5 μm column chromatography (mobile phase A: Hex--HPLC, mobile phase B: EtOH-HPLC; flow rate: 20 mL / min; gradient: 30% B to 30% B in 7 min; UV 220 / 254 nm) to give the following:
[0195] Example 5: 15.3 mg of 1,1,1,3,3,3-hexafluoropropan-2-yl (R)-1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate. 1 H NMR (400 MHz, chloroform-d) δ 12.2-12.0 (m, 1H), 8.87 (s, 1H), 8.75 (br, 1H), 7.66 (br, 1H), 5.80-5.74 (m, 1H), 3.72-3.64 (m, 3H), 3.43-3.37 (m, 1H), 2.49 (t, J = 6.4 Hz, 1H), 1.94-1.86 (m, 2H), 1.70-1.58 (m, 2H), 1.44 (s, 1H), 1.17-1.14 (m, 1H). R =5.118 minutes. LCMS (Method C) (ESI, m / z): 427[M+H] + CHIRALPAK AD, 3.0 * 100 mm, 3 μm; Mobile phase: A phase: CO2, B phase: MeOH (0.1% DEA); Flow rate: 2 mL / min; Gradient: 10% to 50% in 2.0 min, hold at 50% for 1.0 min; Detection: 220 nm:t R =0.814 minutes. and the corresponding enantiomers
[0196] Example 6: 10.1 mg of 1,1,1,3,3,3-hexafluoropropan-2-yl(S)-1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate. 1H NMR(400MHz,クロロホルム-d)δ 11.2(s,1H),8.87(s,1H),8.75(br,1H),7.66(br,1H),5.80-5.74(m,1H),3.72-3.64(m,3H),3.43-3.3 7(m,1H),2.49(t,J=6.4Hz,1H),1.94-1.86(m,2H),1.70-1.58(m,2H),1.44(s,1H),1.17-1.14(m,1H).t R =6.025 points. LCMS (Method C) (ESI, m / z): 427 [M+H] + CHIRALPAK AD, 3.0 * 100mm, 3μm; Mobile phase: Phase A: CO2, Phase B: MeOH (0.1% DEA); Flow rate: 2mL / min; Mixing: 10% to 50% in 2.0 min, 1.0 min in 50%; Emission: 220nm:t R =1.080 points.
[0197] The known intermediate 3B can be synthesized using the method of Example 5:
change
[0198] Note that the retention time of the product prepared here using intermediate 3B matches that of Example 5 prepared above, where the racemic product is separated into its enantiomers by SFC, thus confirming the assigned absolute configuration assigned to Example 5 in the preparation above.
[0199] Synthesis of Example 6 using known intermediate 2B: [ka] A flask purged and maintained under an inert atmosphere of nitrogen was charged with (S)-6-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid (Intermediate 2B) (38.5 g), DCM (800 mL), and DMF (0.40 g). The mixture was cooled to 0 °C, and (COCl) (11.5 g) was added dropwise. The resulting mixture was stirred at room temperature for 3 hours. The mixture was then concentrated in vacuo to provide the crude acyl chloride for further use. A separate flask purged and maintained under an inert atmosphere of nitrogen was charged with pyridazin-3-amine (12.6 g), pyridine (17.4 g), and THF (800 mL). The solution of the acyl chloride in THF (500 mL) was added dropwise at room temperature. The resulting solution was stirred at room temperature overnight. After the reaction was complete, the mixture was diluted with 3 L of ice water and extracted with EtOAc (2 × 1 L). The combined organic phase was washed with HO (1 × 1 L) and brine (1 × 1 L), dried over anhydrous NaSO, and concentrated under vacuum. The residue was purified by silica gel column chromatography using EtOAc / petroleum ether (1 / 10) to give 34.3 g of product. The product was slurried with n-hexane (20 V) and filtered to give 26.7 g of 1,1,1,3,3,3-hexafluoropropan-2-yl (S)-1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate. The product was isolated by slurrying in n-heptane (10V) to give 24.13 g of 1,1,1,3,3,3-hexafluoropropan-2-yl(S)-1-[(pyridazin-3-yl)carbamoyl]-6-azaspiro[2.5]octane-6-carboxylate (Example 6). 1 H NMR(300MHz,chloroform-d)δ 10.82(s,1H),8.87(d,J=4.7Hz,1H),8.61(d,J=9.1Hz,1H),7.55(s,1H),5.90-5.62(m,1H),3.73-3.27(m ,4H),2.26(dd,J=8.0,5.4Hz,1H),1.95-1.72(m,4H),1.41(t,J=5.0Hz,1H),1.11(dd,J=7.9,4.6Hz,1H).t R=1.443 minutes. LCMS (Method O) (ESI, m / z): 427[M+H] + CHIRALPAK AD, 3.0 * 100 mm, 3 mm; Mobile phase: A phase: CO2, B phase: MeOH (0.1% DEA); Flow rate: 2 mL / min; Gradient: 10% to 50% in 2.0 min, hold at 50% for 1.0 min; Detection: 220 nm:t R =1.032 minutes.
[0200] Note that the retention time of the product prepared here using intermediate 2B matches that of Example 6 prepared above, where the racemic product is separated into its enantiomers by SFC, thus confirming the assigned absolute configuration assigned to Example 6 in the preparation above.
[0201] Example 7: 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)-1-((tetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] Step 1: Synthesis of t-butyl 1-((tetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] A flask was charged with 6-(t-butoxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid (300 mg), EDCI (294 mg), HOBT (238 mg), TEA (356 mg), tetrahydro-2H-pyran-4-amine (154 mg), and DCM (5 mL). The reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was then quenched with water (10 mL), extracted with DCM (2 × 15 mL), and concentrated under reduced pressure. The crude product was purified by silica gel chromatography (DCM:MeOH = 20:1) to give t-butyl 1-((tetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (352 mg). LCMS (ESI, m / z): 339 [M+H] + .
[0202] Step 2: Synthesis of N-(tetrahydro-2H-pyran-4-yl)-6-azaspiro[2.5]octane-1-carboxamide [ka] N-(tetrahydro-2H-pyran-4-yl)-6-azaspiro[2.5]octane-1-carboxamide was prepared using t-butyl 1-((tetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (352 mg), TFA (1.5 mL), and DCM (3 mL) as described in Step 2 of Example 1 to give 500 mg (crude) of the title compound. LCMS (ESI, m / z): 239 [M+H] + .
[0203] Step 3: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl(±)1-((tetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] 1,1,1,3,3,3-Hexafluoropropan-2-yl 1-((tetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate was prepared from N-(tetrahydro-2H-pyran-4-yl)-6-azaspiro[2.5]octane-1-carboxamide (480 mg), CDI (392 mg), and 1,1,1,3,3,3-hexafluoropropan-2-ol (3389 mg) as described in Step 3 of Example 1 to obtain a crude product (377 mg). The crude product was purified by reverse-phase column chromatography to obtain the title compound (88 mg).
[0204] Example 8: 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-((tetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate and Example 9: 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((tetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] The racemic mixture (88 mg) prepared in Example 7 was purified by preparative SFC-HPLC (column: CHIRAL ART Amylose-C NEO, 3 * The two enantiomers were separated by HPLC (25 cm, 5 μm; mobile phase A: CO, mobile phase B: EtOH (0.5% 2M NH-MeOH)—HPLC; flow rate: 50 mL / min; gradient: 15% B; column temperature: 35° C.; back pressure: 100 bar; UV 220 nm) to give:
[0205] Example 8: 13 mg of 1,1,1,3,3,3-hexafluoropropan-2-yl (S)-1-((tetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate 1H NMR(400MHz,chloroform-d)δ 5.78(dq,J=12.0,6.1Hz,1H),5.52(d,J=7.9Hz,1H),4.09-3.93(m,3H),3.72-3.40(m,6H),1.97-1.87(m,2H),1.81(dd,J=10.9,5 .4Hz,2H),1.56-1.50(m,2H),1.50-1.40(m,2H),1.34(dd,J=8.0,5.3Hz,1H),1.27(d,J=4.6Hz,1H),0.88(dd,J=8.0,4.5Hz,1H).t R =4.32 minutes. LCMS (Method D) (ESI, m / z): 433[M+H] + (S,S)Whelk-01, 4.6 * 100 mm, 5 μm; Mobile phase: A phase: CO2, B phase: IPA (0.1% DEA); Flow rate: 4 mL / min; Gradient: 5% to 20% in 2.0 min, hold at 20% for 1.0 min; Detection: 220 nm:t R =1.568 minutes. and the corresponding enantiomers
[0206] Example 9: 15.4 mg of 1,1,1,3,3,3-hexafluoropropan-2-yl (R)-1-((tetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate 1 H NMR(400MHz,chloroform-d)δ 5.78(m,J=6.0Hz,1H),5.51(d,J=8.0Hz,1H),4.21-3.87(m,3H),3.87-3.03(m,6H),1.93(ddd,J=12.9,4.4,2.2Hz,2H),1.87-1.7 0(m,2H),1.55-1.48(m,2H),1.48-1.38(m,2H),1.34(dd,J=8.0,5.3Hz,1H),1.27(d,J=4.6Hz,1H),0.88(dd,J=8.0,4.5Hz,1H).t R =4.99 minutes. LCMS (Method A) (ESI, m / z): 433[M+H] + (S,S)Whelk-01, 4.6 *100 mm, 5 μm; Mobile phase: A phase: CO2, B phase: IPA (0.1% DEA); Flow rate: 4 mL / min; Gradient: 5% to 20% in 2.0 min, hold at 20% for 1.0 min; Detection: 220 nm:t R =1.425 minutes.
[0207] Synthesis of Example 8 using known intermediate 2B: [ka] A flask purged and maintained under an inert atmosphere of nitrogen was charged with (S)-6-[[(1,1,1,3,3,3-hexafluoropropan-2-yl)oxy]carbonyl]-6-azaspiro[2.5]octane-1-carboxylic acid (Intermediate 2B) (21.0 g), DCM (400 mL), and DMF (0.22 g). The mixture was cooled to 0 °C, and (COCl) (11.5 g) was added dropwise. The resulting mixture was stirred at room temperature for 3 hours. The mixture was then concentrated under vacuum to provide the crude acyl chloride for further use. A separate flask purged and maintained under an inert atmosphere of nitrogen was charged with oxan-4-amine (7.3 g), pyridine (9.5 g), and THF (400 mL). A solution of the acyl chloride in THF (200 mL) was added dropwise at room temperature. The resulting solution was stirred at room temperature overnight. After the reaction was complete, the mixture was diluted with ice water (1 × 3 L) and extracted with EtOAc (2 × 500 mL). The combined organic phase was washed with HO (1 × 1 L) and brine (1 × 1 L), dried over anhydrous NaSO, and concentrated under vacuum. The residue was purified by silica gel column chromatography using EtOAc / petroleum ether (1 / 10) to give 20.7 g of product. The product was further purified by silica gel column chromatography using 0.1% NHHCO in HO-MeCN system to give 15.2 g of amorphous product. The product was finally recrystallized from MeCN / HO = 1:1 (0.5 V / 0.5 V) to give 11.97 g of 1,1,1,3,3,3-hexafluoropropan-2-yl (S)-1-[(oxan-4-yl)carbamoyl]-6-azaspiro[2.5]octane-6-carboxylate. 1H NMR (300 MHz, chloroform-d) δ 5.76 (s, 1H), 5.49 (d, J = 8.0 Hz, 1H), 3.96 (d, J = 12.1 Hz, 3H), 3.72-3.34 (m, 6H), 2.00-1.72 (m, 4H), 1.54-1.37 (m, 4H), 1.35-1.20 (m, 2H), 0.86 (dd, J = 7.9, 4.4 Hz, 1H). R =1.442 minutes. LCMS (Method O) (ESI, m / z): 433[M+H] + (S,S)Whelk-01, 4.6 * 100 mm, 5 mm; Mobile phase: A phase: CO2, B phase: IPA (0.1% DEA); Flow rate: 4 mL / min; Gradient: 5% to 20% in 2.0 min, hold at 20% for 1.0 min; Detection: 220 nm:t R =1.525 minutes.
[0208] Note that the retention time of the product prepared here using intermediate 2B matches that of Example 8 prepared above, where the racemic product is separated into its enantiomers by SFC, thus confirming the assigned absolute configuration assigned to Example 8 in the preparation above.
[0209] Synthesis of Example 9 using known intermediate 3B: [ka] A reaction vial was charged with a solution of crude (R)-6-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid (Intermediate 3B) (50 mg) and DCM (1 mL). EDC·HCl (30.3 mg) and HOBt (38.7 mg) were added, and the resulting mixture was stirred for 15 min. Tetrahydro-2H-pyran-4-amine (18.8 mg) and DIEA (37.0 mg) were added. The reaction mixture was stirred at room temperature overnight. The mixture was diluted with HO (10 mL) and extracted with DCM (1 × 5 mL). The combined organic phase was dried over anhydrous NaSO, filtered, and concentrated. The crude product was purified by preparative HPLC to give 1,1,1,3,3,3-hexafluoropropan-2-yl (R)-1-((tetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (37 mg). 1H NMR (300 MHz, chloroform-d) δ 5.76 (td, J = 6.1, 3.3 Hz, 1H), 5.50 (d, J = 8.0 Hz, 1H), 3.96 (d, J = 12.5 Hz, 3H), 3.70-3.36 (m, 6H), 1.98-1.72 (m, 4H), 1.55-1.39 (m, 4H), 1.37-1.19 (m, 2H), 0.86 (dd, J = 7.9, 4.4 Hz, 1H). R =1.442 minutes. LCMS (Method P) (ESI, m / z): 433[M+H] + (S,S)Whelk-01, 4.6 * 100 mm, 5 mm; Mobile phase: A phase: CO2, B phase: IPA (0.1% DEA); Flow rate: 4 mL / min; Gradient: 5% to 20% in 2.0 min, hold at 20% for 1.0 min; Detection: 220 nm:t R =1.46 minutes.
[0210] Note that the retention time of the product prepared here using intermediate 3B matches that of Example 9 prepared above, where the racemic product is separated into its enantiomers by SFC, thus confirming the assigned absolute configuration assigned to Example 9 in the preparation above.
[0211] Example 10: 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(methyl(pyrazin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] Step 1: Synthesis of t-butyl 1-(pyrazin-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] t-Butyl 1-(pyrazin-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate was prepared from 6-(t-butoxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid (500 mg), DCM (10 mL), DMF (14.0 mg), oxalyl chloride (249 mg), pyrazin-2-amine (186 mg), pyridine (464 mg), and t-butyl 1-(carbonochloridoyl)-6-azaspiro[2.5]octane-6-carboxylate as described in Step 1 of Example 1 to give the title compound (190 mg). LCMS (ESI, m / z): 333 [M+H] + .
[0212] Step 2: Synthesis of t-butyl 1-(methyl(pyrazin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] A vial was charged with t-butyl 1-(pyrazin-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (190 mg) and THF (5 mL). Sodium hydride (34.3 mg, 0.858 mmol, 1.50 equiv, 60% in mineral oil) was added at 0°C. The resulting solution was stirred at 0°C for 0.5 h, and then methyl iodide (97.4 mg) was added. The resulting solution was stirred at room temperature overnight and quenched with water (10 mL). The mixture was extracted with EtOAc (3 × 10 mL), and the combined organic layers were washed with brine (3 × 10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was chromatographed on a silica gel column to give t-butyl 1-(methyl(pyrazin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (140 mg). LCMS (ESI, m / z): 347 [M+H] + .
[0213] Step 3: Synthesis of N-methyl-N-(pyrazin-2-yl)-6-azaspiro[2.5]octane-1-carboxamide [ka] N-Methyl-N-(pyrazin-2-yl)-6-azaspiro[2.5]octane-1-carboxamide was prepared from t-butyl 1-(methyl(pyrazin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (140 mg), TFA (3 mL), and DCM (3 mL) as described in Step 2 of Example 1 to give the title compound (99.7 mg). LCMS (ESI, m / z): 247 [M+H] + .
[0214] Step 4: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl(±)1-(methyl(pyrazin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] A vial was charged with 1,1,1,3,3,3-hexafluoropropan-2-ol (102 mg, 0.606 mmol, 1.50 equiv), DCM (10 mL), and triphosgene (67.8 mg). DIPEA (156 mg) was added at 0° C. The resulting solution was stirred at room temperature for 2 hours, and then N-methyl-N-(pyrazin-2-yl)-6-azaspiro[2.5]octane-6-1-carboxamide (99.7 mg) was added. The resulting solution was stirred at room temperature overnight and then quenched with water (10 mL). The solution was extracted with DCM (3 × 10 mL), and the organic layers were combined, washed with brine (3 × 10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to provide the title compound.
[0215] Example 11: 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(methyl(pyrazin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate Peak 1 and Example 12: 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(methyl(pyrazin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate Peak 2 [ka] The racemic mixture prepared in Example 10 was purified by preparative chiral HPLC (column: CHIRALPAK IA Column 2 * The two enantiomers were separated by HPLC (25 cm, 5 μm; mobile phase A: Hex--HPLC, mobile phase B: EtOH--HPLC; flow rate: 20 mL / min; gradient: 30% B to 30% B in 11 min; UV 220 and 254 nm) to give the following:
[0216] Example 11: 12.5 mg of 1,1,1,3,3,3-hexafluoropropan-2-yl(R)-1-(methyl(pyrazin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate Peak 1. 1H NMR (400 MHz, chloroform-d) δ 8.79 (s, 1H), 8.45 (d, J = 7.31 Hz, 2H), 5.83-5.76 (m, 1H), 3.82-3.75 (m, 2H), 3.52 (s, 3H), 3.46-3.37 (m, 2H), 1.88-1.79 (m, 1H), 1.73-1.62 (m, 3H), 1.48-1.45 (m, 1H), 1.33-1.26 (m, 1H), 0.91-0.88 (m, 1H). R =7.897 minutes. LCMS (Method E) (ESI, m / z): 441[M+H] + . and the corresponding enantiomers
[0217] Example 12: 12.1 mg of 1,1,1,3,3,3-hexafluoropropan-2-yl(S)-1-(methyl(pyrazin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate peak 2. 1 H NMR (400 MHz, chloroform-d) δ 8.79 (s, 1H), 8.46 (d, J = 7.50 Hz, 2H), 5.83-5.75 (m, 1H), 3.81-3.76 (m, 2H), 3.52 (s, 3H), 3.45-3.37 (m, 2H), 1.88-1.79 (m, 1H), 1.72-1.59 (m, 3H), 1.47-1.45 (m, 1H), 1.33-1.26 (m, 1H), 0.92-0.88 (m, 1H). R =9.487 minutes. LCMS (Method E) (ESI, m / z): 441[M+H] + .
[0218] Determination of the absolute configuration of Examples 11 and 12 The absolute configurations of Examples 11 and 12 were determined in a manner similar to that of Example 3, and the absolute configurations of the final products (Examples 11 and 12) could be assigned by resynthesis of the final compounds using intermediates of known absolute configuration. Ultimately, it was determined that the first eluted enantiomer was the (R) enantiomer (Example 11), and therefore Example 12 was the (S)-enantiomer.
[0219] Example 13: 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)-1-(isoxazol-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] Step 1: Synthesis of 1-benzyl 6-(t-butyl) 6-azaspiro[2.5]octane-1,6-dicarboxate [ka] A vial was charged with 6-(t-butoxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid (300 mg), acetone (15 mL), KCO (195 mg), and BnBr (220 mg). The resulting solution was stirred at 60 °C overnight and quenched with water (20 mL). The mixture was extracted with EtOAc (3 × 20 mL), and the combined organic layers were washed with brine (3 × 20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was chromatographed on a silica gel column using EtOAc to give 1-benzyl 6-(t-butyl) 6-azaspiro[2.5]octane-1,6-dicarboxyl (350 mg). LCMS (ESI, m / z): 346 [M+H] + .
[0220] Step 2: Synthesis of benzyl 6-azaspiro[2.5]octane-1-carboxylate [ka] To a solution of 1-benzyl 6-(t-butyl) 6-azaspiro[2.5]octane-1,6-dicarboxlate (350 mg) in DCM (6 mL) was added HCl (g) (3 mL). The resulting solution was stirred at room temperature for 2 hours and concentrated under reduced pressure to give benzyl 6-azaspiro[2.5]octane-6-1-carboxylate (260 mg). LCMS (ESI, m / z): 246 [M+H] + .
[0221] Step 3: Synthesis of 1-benzyl 6-(1,1,1,3,3,3-hexafluoropropan-2-yl) 6-azaspiro[2.5]octane-1,6-dicarboxate [ka] 1-Benzyl 6-(1,1,1,3,3,3-hexafluoropropan-2-yl)6-azaspiro[2.5]octane-1,6-dicarboxate was prepared from benzyl 6-azaspiro[2.5]octane-1-carboxylate (240 mg), ACN (4 mL), 1,1'-carbonyldiimidazole (205 mg), DIPEA (378 mg), and 1,1,1,3,3,3-hexafluoropropan-2-ol (820 mg) as described in Step 3 of Example 1 to give 1-benzyl 6-(1,1,1,3,3,3-hexafluoropropan-2-yl)6-azaspiro[2.5]octane-1,6-dicarboxate (350 mg). LCMS (ESI, m / z): 440 [M+H] + .
[0222] Step 4: Synthesis of 6-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid [ka] A mixture of 1-benzyl 6-(1,1,1,3,3,3-hexafluoropropan-2-yl)6-azaspiro[2.5]octane-1,6-dicarboxate (340 mg) and Pd / C (40 mg, 10% wt) in EtOAc (10 mL) was stirred overnight under H. The reaction was cooled to room temperature and filtered. The filtrate was concentrated under reduced pressure to give 6-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid (240 mg). LCMS (ESI, m / z): 350 [M+H] + .
[0223] Step 5: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl(±)1-(isoxazol-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(isoxazol-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate was prepared from 6-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid (100 mg), isoxazol-4-amine (44.7 mg), EDCI (60.5 mg), HOBT (38.7 mg), and TEA (86.8 mg) in DCM (2 mL) as described in Step 1 of Example 5 to give the title compound (70 mg).
[0224] Example 14: 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(isoxazol-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate Peak 1, and Example 15: 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(isoxazol-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate Peak 2 [ka] The racemic mixture (70 mg) prepared in Example 10 was purified by preparative chiral HPLC (column: CHIRALPAK IG, 2 * The two enantiomers were separated by HPLC (25 cm, 5 μm; mobile phase A: Hex (0.5% 2M NH3-MeOH) - HPLC, mobile phase B: IPA - HPLC; flow rate: 20 mL / min; gradient: 20% B to 30% B in 7.5 min; detectors: UV 220 and 254 nm) to give the following:
[0225] Example 14: 15.0 mg of 1,1,1,3,3,3-hexafluoropropan-2-yl(S)-1-(isoxazol-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate Peak 1. 1 H NMR (400 MHz, chloroform-d) δ 8.96 (s, 1H), 8.37 (s, 1H), 7.48 (s, 1H), 5.86-5.70 (m, 1H), 3.79-3.66 (m, 1H), 3.65-3.43 (m, 3H), 1.93-1.75 (m, 2H), 1.69-1.42 (m, 3H), 1.41-1.34 (m, 1H), 1.11-0.99 (m, 1H). R =5.612 minutes. LCMS (Method E) (ESI, m / z): 416[M+H] + . and the corresponding enantiomers
[0226] Example 15: 9.7 mg of 1,1,1,3,3,3-hexafluoropropan-2-yl (R)-1-(isoxazol-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate peak 2. 1 H NMR (400 MHz, chloroform-d) δ 8.96 (s, 1H), 8.37 (s, 1H), 7.48 (s, 1H), 5.84-5.70 (m, 1H), 3.79-3.65 (m, 1H), 3.64-3.42 (m, 3H), 1.93-1.76 (m, 2H), 1.70-1.42 (m, 3H), 1.41-1.35 (m, 1H), 1.10-0.99 (m, 1H). R =6.706 minutes. LCMS (Method E) (ESI, m / z): 416[M+H] + .
[0227] Determination of the absolute configuration of Examples 14 and 15 The absolute configurations of Examples 14 and 15 were determined in a manner similar to that of Example 3, and the absolute configurations of the final products (Examples 14 and 15) could be assigned by resynthesis of the final compounds using intermediates of known absolute configuration. Ultimately, it was determined that the second eluting enantiomer was the (R) enantiomer (Example 15), and therefore Example 14 was the (S)-enantiomer.
[0228] Example 16: 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)-1-((2-(trifluoromethyl)pyrimidin-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] Step 1: Synthesis of t-butyl 1-(chlorocarbonyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] A vial was charged with 6-(t-butoxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid (255 mg) and DCM (10 mL). 1-Chloro-N,N,2-trimethylprop-1-en-1-amine (201 mg) was added dropwise at 0° C. The resulting solution was stirred at room temperature for 2 hours and concentrated under reduced pressure to give t-butyl 1-(chlorocarbonyl)-6-azaspiro[2.5]octane-6-carboxylate (274 mg).
[0229] Step 2: Synthesis of t-butyl 1-((2-(trifluoromethyl)pyrimidin-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] A vial was charged with 2-(trifluoromethyl)pyrimidin-4-amine (200 mg) and THF (15 mL). Sodium hydride (49.0 mg, 1.23 mmol, 2.00 equiv, 60% in mineral oil) was added at 0° C. The resulting suspension was stirred at room temperature for 0.5 h, and t-butyl 1-(chlorocarbonyl)-6-azaspiro[2.5]octane-6-carboxylate (252 mg) was added. The resulting solution was stirred at room temperature overnight and quenched by the addition of water (10 mL). The mixture was extracted with EtOAc (3×20 mL), and the combined organic layers were washed with brine (2×20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was chromatographed on a silica gel column with EtOAc / petroleum ether (1:3) to give t-butyl 1-((2-(trifluoromethyl)pyrimidin-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (240 mg). LCMS (ESI, m / z): 401 [M+H] + .
[0230] Step 3: Synthesis of N-(2-(trifluoromethyl)pyrimidin-4-yl)-6-azaspiro[2.5]octane-1-carboxamide [ka] N-(2-(trifluoromethyl)pyrimidin-4-yl)-6-azaspiro[2.5]octane-1-carboxamide was prepared using t-butyl 1-((2-(trifluoromethyl)pyrimidin-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (240 mg), 1,4-dioxane (4 mL), and concentrated hydrochloric acid (1 mL) as described in Step 2 of Example 13 to give the title compound (180 mg). LCMS (ESI, m / z): 301 [M+H] + .
[0231] Step 4: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl(±)-1-((2-(trifluoromethyl)pyrimidin-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)-1-((2-(trifluoromethyl)pyrimidin-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate was prepared from N-(2-(trifluoromethyl)pyrimidin-4-yl)-6-azaspiro[2.5]octane-6-1-carboxamide (0.180 g), carbonyldiimidazole (0.146 g), ACN (15 mL), and 1,1,1,3,3,3-hexafluoropropan-2-ol (1.21 g) as described in Step 3 of Example 1 to give the title compound.
[0232] Example 17: 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-((2-(trifluoromethyl)pyrimidin-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate Peak 1 and Example 18: 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((2-(trifluoromethyl)pyrimidin-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate Peak 2 [ka] The racemic mixture prepared in Example 16 was subjected to preparative chiral HPLC (column: CHIRALPAK AD-H, 2 * The two enantiomers were separated by a 25 cm, 5 μm column chromatography (mobile phase A: Hex--HPLC, mobile phase B: EtOH-HPLC; flow rate: 20 mL / min; gradient: 5% B to 5% B in 11 min; UV 220 / 254 nm) to give the following:
[0233] Example 17: 15.8 mg 1,1,1,3,3,3-hexafluoropropan-2-yl(S)-1-((2-(trifluoromethyl)pyrimidin-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate Peak 1. 1 H NMR(400MHz,chloroform-d)δ 8.78(d,J=5.6Hz,1H),8.50-8.20(m,2H),5.77(br,1H),3.84-3.68(m,1H),3.68-3. 38(m,3H),1.85(br,2H),1.68-1.58(m,2H),1.58-1.40(m,2H),1.22-1.02(m,1H).t R =7.674 minutes. LCMS (Method F) (ESI, m / z): 495[M+H] + . and the corresponding enantiomers
[0234] Example 18: 17.2 mg 1,1,1,3,3,3-hexafluoropropan-2-yl (R)-1-((2-(trifluoromethyl)pyrimidin-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate Peak 2. 1 H NMR(400MHz,chloroform-d)δ 8.78(d,J=5.6Hz,1H),8.50-8.20(m,2H),5.77(br,1H),3.84-3.68(m,1H),3.68-3. 38(m,3H),1.85(br,2H),1.68-1.58(m,2H),1.58-1.40(m,2H),1.22-1.02(m,1H).t R =9.747 minutes. LCMS (Method F) (ESI, m / z): 495[M+H] + .
[0235] Determination of the absolute configuration of Examples 17 and 18 The absolute configurations of Examples 17 and 18 were determined in a manner similar to that of Example 3, and the absolute configurations of the final products (Examples 17 and 18) could be assigned by resynthesis of the final compounds using intermediates of known absolute configuration. Ultimately, it was determined that the second eluting enantiomer was the (R) enantiomer (Example 18), and therefore Example 17 was the (S)-enantiomer.
[0236] Example 19: 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)-1-((6-(dimethylphosphoryl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] Step 1: Synthesis of t-butyl 1-((6-iodopyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] To a stirred solution of 6-(t-butoxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid (500.00 mg), HATU (1116.95 mg), and DIEA (759.32 mg) in DMF (10.00 mL) was added 6-iodopyridin-3-amine (430.87 mg) at room temperature. The resulting mixture was stirred overnight and quenched with water (50 mL). The resulting mixture was extracted with EtOAc (3 × 50 mL), and the combined organic layers were washed with brine (3 × 30 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse flash chromatography using a C18 silica gel column, MeOH in water, 10% to 50% gradient in 10 min, UV 254 / 220 nm detector to give t-butyl 1-((6-iodopyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (700 mg). LCMS (ESI, m / z): 458 [M+H]. + .
[0237] Step 2: Synthesis of t-butyl 1-((6-(dimethylphosphoryl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] A mixture of t-butyl 1-((6-iodopyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (700.00 mg), Pd(dba) (140.17 mg), Xantphos (88.57 mg), EtN (464.67 mg), and (methylphosphonoyl)methane (238.94 mg) in 1,4-dioxane (10.00 mL) was stirred at 80 °C overnight under a nitrogen atmosphere. The resulting mixture was cooled to room temperature, quenched with water (50 mL), and extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with brine (3 × 30 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse flash chromatography using a C18 silica gel column; a mobile phase of MeOH in water, 10% to 50% gradient in 10 min; and UV detection at 254 / 220 nm to give t-butyl 1-((6-(dimethylphosphoryl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (560 mg). LCMS (ESI, m / z): 408 [M+H]+.
[0238] Step 3: Synthesis of N-(6-(dimethylphosphoryl)pyridin-3-yl)-6-azaspiro[2.5]octane-1-carboxamide hydrochloride [ka] N-(6-(dimethylphosphoryl)pyridin-3-yl)-6-azaspiro[2.5]octane-1-carboxamide hydrochloride was prepared from t-butyl 1-[[6-(dimethylphosphoryl)pyridin-3-yl]carbamoyl]-6-azaspiro[2.5]octane-6-carboxylate (560.00 mg), DCM (5.00 mL), and HCl (g) (4 min 1,4-dioxane, 5.00 mL, 20 mmol) as described in Step 2 of Example 13 to afford the title compound (400 mg). The crude product was used directly in the next step without further purification. LCMS (ESI, m / z): 308 [M-HCl+H] + .
[0239] Step 4: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl(±)-1-((6-(dimethylphosphoryl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] 1,1,1,3,3,3-Hexafluoropropan-2-yl (±)-1-((6-(dimethylphosphoryl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate was prepared from N-(6-(dimethylphosphoryl)pyridin-3-yl)-6-azaspiro[2.5]octane-1-carboxamide hydrochloride (350.00 mg), DIPEA (525.00 mg), hexafluoroisopropanol (341.86 mg), and CDI (214.33 mg) in MeCN (10.00 mL) as described in Step 3 of Example 1 to give the title compound (400 mg). LCMS (ESI, m / z): 502 [M+H] + .
[0240] Example 20: 1,1,1,3,3,3-Hexafluoropropan-2-yl (R or S)-1-((6-(dimethylphosphoryl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate Peak 1 Example 21: 1,1,1,3,3,3-Hexafluoropropan-2-yl (R or S)-1-((6-(dimethylphosphoryl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate Peak 2 [ka] The racemic mixture prepared in Example 19 was purified by chiral HPLC (HIRAL ART Cellulose-SB, 2 * The two enantiomers were separated by HPLC (25 cm, 5 μm; mobile phase A: Hex (0.2% DEA) - HPLC, mobile phase B: EtOH:DCM = 1:1 - HPLC; flow rate: 20 mL / min; gradient: 10% B to 10% B in 21 min; UV 220 / 254 nm) to give the following:
[0241] Example 20: 135.2 mg 1,1,1,3,3,3-hexafluoropropan-2-yl (R or S)-1-((6-(dimethylphosphoryl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate Peak 1. 1 H NMR(400MHz,DMSO-d6)δ 10.67(s,1H),8.89-8.87(m,1H),8.22 -8.18(m,1H),7.90-7.86(m,1H),6.59-6.54(m,1H),3.62-3.56(m,2H),3.54-3.49(m,1H),3.33(s,1H), 1.87-1.83(m,1H),1.69(s,2H),1.65-1.59(m,6H),1.51(s,2H),1.20-1.11(m,1H),1.06-0.99(m,1H).t R =8.88 minutes. LCMS (Method D) (ESI, m / z): 502[M+H] + . and the corresponding enantiomers
[0242] Example 21: 122.5 mg 1,1,1,3,3,3-hexafluoropropan-2-yl (R or S)-1-((6-(dimethylphosphoryl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate Peak 2. 1 H NMR(400MHz,DMSO-d6)δ 10.67(s,1H),8.89-8.87(m,1H),8.22 -8.18(m,1H),7.90-7.86(m,1H),6.59-6.54(m,1H),3.62-3.56(m,2H),3.55-3.47(m,1H),3.33(s,1H), 1.89-1.81(m,1H),1.70(s,1H),1.66-1.59(m,7H),1.51(s,2H),1.21-1.11(m,1H),1.06-0.98(m,1H).t R =11.641 minutes. LCMS (Method D) (ESI, m / z): 502[M+H] + .
[0243] Example 22: 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)-1-(pyridin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] Step 1: Synthesis of t-butyl 1-carbamoyl-6-azaspiro[2.5]octane-6-carboxylate [ka] A mixture of 6-(t-butoxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid (600 mg, 2.34 mmol, 1.00 equiv.), HATU (1069 mg, 2.80 mmol, 1.20 equiv.), DIPEA (15.2 mg, 11.2 mmol, 5.00 equiv.), and NH4Cl (620 mg, 11.7 mmol, 5.00 equiv.) in DMF (10 mL) was stirred at room temperature overnight. The resulting mixture was quenched with water (50 mL). The aqueous layer was extracted with EtOAc (2 × 200 mL). The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with EtOAc / petroleum ether (8:1) to give t-butyl 1-carbamoyl-6-azaspiro[2.5]octane-6-carboxylate (500 mg). LCMS(ESI,m / z):255[M+H] + .
[0244] Step 2: Synthesis of t-butyl 1-(pyridin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] A mixture of t-butyl 1-carbamoyl-6-azaspiro[2.5]octane-6-carboxylate (400 mg), 4-iodopyridine (386 mg), K2CO3 (433 mg), Ln (22 mg), and CuI (15 mg) in toluene (30 mL) was stirred overnight at 100 °C under a nitrogen atmosphere. The resulting mixture was quenched with water (50 mL). The aqueous layer was extracted with EtOAc (2 × 200 mL), and the resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with EtOAc / petroleum ether (8:1) to give t-butyl 1-(pyridin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (360 mg). LCMS (ESI, m / z): 332 [M+H] + .
[0245] Step 3: Synthesis of N-(pyridin-4-yl)-6-azaspiro[2.5]octane-1-carboxamide [ka] N-(pyridin-4-yl)-6-azaspiro[2.5]octane-1-carboxamide was prepared from t-butyl 1-(pyridin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (360 mg), DCM (5 mL), and HCl (gas) / 1,4-dioxane (3 mL) as described in Step 2 of Example 13 to give the title compound (200 mg). LCMS (ESI, m / z): 232 [M+H] + .
[0246] Step 4: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl(±)-1-(pyridin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)-1-(pyridin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate was prepared from N-(pyridin-4-yl)-6-azaspiro[2.5]octane-6-1-carboxamide (440 mg), CDI (369 mg), ACN (5 mL), DIPEA (489 mg), and 1,1,1,3,3,3-hexafluoropropan-2-ol (1603 mg) as described in Step 3 of Example 1 to give the title compound (100 mg).
[0247] Example 23: 1,1,1,3,3,3-Hexafluoropropan-2-yl (R or S)-1-(pyridin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate Peak 1 and Example 24: 1,1,1,3,3,3-Hexafluoropropan-2-yl (R or S)-1-(pyridin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate Peak 2 [ka] The racemic mixture prepared in Example 22 was purified by chiral HPLC (CHIRALPAK IF, 2 * The two enantiomers were separated by HPLC (25 cm, 5 μm; mobile phase A: Hex (10 mM NH3-MeOH), mobile phase B: EtOH; flow rate: 15 mL / min; gradient: 5% B to 5% B in 15 min; UV 220 / 254 nm) to give:
[0248] Example 23: 32.9 mg of 1,1,1,3,3,3-hexafluoropropan-2-yl (R or S)-1-(pyridin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate Peak 1. 1 H NMR (400 MHz, chloroform-d) δ 9.11-8.88 (m, 1H), 8.59-8.30 (m, 2H), 7.68-7.44 (m, 2H), 5.79-5.60 (m, 1H), 3.80-3.36 (m, 4H), 1.96-1.77 (m, 2H), 1.73-1.51 (m, 2H), 1.50-1.34 (m, 2H), 1.08-0.99 (m, 1H). R =9.807 minutes. LCMS (Method E) (ESI, m / z): 426[M+H] + . and the corresponding enantiomers
[0249] Example 24: 32.2 mg of 1,1,1,3,3,3-hexafluoropropan-2-yl (R or S)-1-(pyridin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate peak 2. 1 H NMR (400 MHz, chloroform-d) δ 9.11-8.88 (m, 1H), 8.59-8.30 (m, 2H), 7.68-7.44 (m, 2H), 5.79-5.60 (m, 1H), 3.80-3.36 (m, 4H), 1.96-1.77 (m, 2H), 1.73-1.51 (m, 2H), 1.50-1.34 (m, 2H), 1.08-0.99 (m, 1H). R=11.917 minutes. LCMS (Method E) (ESI, m / z): 426[M+H] + .
[0250] Example 25: 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((tetrahydro-2H-pyran-4-carbonyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] Step 1: Synthesis of t-butyl 1-carbamoyl-6-azaspiro[2.5]octane-6-carboxylate [ka] t-Butyl 1-carbamoyl-6-azaspiro[2.5]octane-6-carboxylate was prepared from 6-(t-butoxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid (600 mg, 2.34 mmol, 1.00 equiv.), HATU (1069 mg, 2.80 mmol, 1.20 equiv.), DIPEA (15.2 mg, 11.2 mmol, 5.00 equiv.), and NHCl (620 mg, 11.7 mmol, 5.00 equiv.) in DMF (10 mL) as described in Step 1 of Example 19 to give t-butyl 1-carbamoyl-6-azaspiro[2.5]octane-6-carboxylate (500 mg). LCMS (ESI, m / z): 255 [M+H] + .
[0251] Step 2: Synthesis of t-butyl 1-((tetrahydro-2H-pyran-4-carbonyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] To a mixture of tetrahydro-2H-pyran-4-carboxylic acid (500.00 mg) and oxalyl chloride (961 mg) in DCM (10 mL) was added DMF (30.0 mg) dropwise at room temperature. The reaction mixture was stirred at room temperature for 1 hour. After the reaction mixture was concentrated under reduced pressure, t-butyl 1-carbamoyl-6-azaspiro[2.5]octane-6-carboxylate (150 mg) and lutidine (127 mg) in DCM were added. The resulting reaction mixture was stirred overnight at room temperature and quenched with water (10 mL). The resulting mixture was extracted with DCM (3 × 30 mL), and the combined organic layers were washed with brine (2 × 30 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography to give t-butyl 1-((tetrahydro-2H-pyran-4-carbonyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (230 mg). LCMS (ESI, m / z): 367 [M+H] + .
[0252] Step 3. Synthesis of N-(tetrahydro-2H-pyran-4-carbonyl)-6-azaspiro[2.5]octane-1-carboxamide [ka] N-(tetrahydro-2H-pyran-4-carbonyl)-6-azaspiro[2.5]octane-1-carboxamide was prepared from a solution of t-butyl 1-((tetrahydro-2H-pyran-4-carbonyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (230 mg), DCM (5 mL), and HCl (gas) / 1,4-dioxane (3 mL) as described in Step 2 of Example 13 to give N-(tetrahydro-2H-pyran-4-carbonyl)-6-azaspiro[2.5]octane-1-carboxamide (130 mg). LCMS (ESI, m / z): 267 [M+H] + .
[0253] Step 4: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl(±)1-((tetrahydro-2H-pyran-4-carbonyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] 1,1,1,3,3,3-Hexafluoropropan-2-yl (±)1-((tetrahydro-2H-pyran-4-carbonyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate was prepared from N-(tetrahydro-2H-pyran-4-carbonyl)-6-azaspiro[2.5]octane-1-carboxamide (200 mg), CDI (146 mg), ACN (5 mL), DIPEA (489 mg, 3.79 mmol, 2.00 equiv.), and 1,1,1,3,3,3-hexafluoropropan-2-ol (634 mg) as described in Step 3 of Example 1 to afford the title compound (100 mg).
[0254] Example 26: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl (R or S)-1-((tetrahydro-2H-pyran-4-carbonyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate Peak 1 Example 27: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl (R or S)-1-((tetrahydro-2H-pyran-4-carbonyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate Peak 2 [ka] The racemic mixture (100 mg) prepared in Example 25 was purified by chiral HPLC (CHIRALPAKIF, 2 * The two enantiomers were separated by HPLC (25 cm, 5 μm; mobile phase A: Hex (10 mM NH3-MeOH), mobile phase B: EtOH; flow rate: 20 mL / min; gradient: 10% B to 10% Bn in 25 min; UV 220 / 254 nm) to give:
[0255] Example 26: 41.5 mg of 1,1,1,3,3,3-hexafluoropropan-2-yl (R or S)-1-((tetrahydro-2H-pyran-4-carbonyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate Peak 1. 1 H NMR(400MHz,chloroform-d)δ 8.43-8.31(m,1H),5.91-5.69(m,1H),4.15-3.96(m,2H),3.78-3.59(m,3H),3.56-3.39(m,2H),3.34-3.20(m,1H),2.90-2.7 4(m,1H),2.50-2.40(m,1H),1.90-1.77(m,4H),1.73-1.62(m,3H),1.60-1.51(m,1H),1.48-1.39(m,1H),1.11-1.01(m,1H).t R =8.356 minutes. LCMS (Method A) (ESI, m / z): 461[M+H] + . and the corresponding enantiomers
[0256] Example 27: 24.7 mg of 1,1,1,3,3,3-hexafluoropropan-2-yl (R or S)-1-((tetrahydro-2H-pyran-4-carbonyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate peak 2. 1 H NMR(400MHz,chloroform-d)δ 8.43-8.31(m,1H),5.91-5.69(m,1H),4.15-3.96(m,2H),3.78-3.59(m,3H),3.56-3.39(m,2H),3.34-3.20(m,1H),2.90-2.7 4(m,1H),2.50-2.40(m,1H),1.90-1.77(m,4H),1.73-1.62(m,3H),1.60-1.51(m,1H),1.48-1.39(m,1H),1.11-1.01(m,1H).t R =16.403 minutes. LCMS (Method A) (ESI, m / z): 461[M+H] + .
[0257] Example 28: 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((6-(1H-pyrazol-1-yl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] Step 1. Synthesis of 5-nitro-2-(1H-pyrazol-1-yl)pyridine [ka] A vial was charged with 2-fluoro-5-nitropyridine (1.00 g, 7.04 mmol, 1.00 equiv), 1H-pyrazole (575 mg), CsCO (5.10 mg), and DMF (10 mL). The resulting solution was stirred at 100 °C overnight and quenched with water (20 mL). The mixture was extracted with EtOAc (3 × 20 mL), and the combined organic layers were washed with brine (3 × 20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography to give 5-nitro-2-(1H-pyrazol-1-yl)pyridine (1.00 g). LCMS (ESI, m / z): 191 [M+H] + .
[0258] Step 2: Synthesis of 6-(1H-pyrazol-1-yl)pyridin-3-amine [ka] A mixture of 5-nitro-2-(1H-pyrazol-1-yl)pyridine (1.00 g) and Pd / C (20 mg, 10% wt) in MeOH (10 mL) was stirred overnight under H. The reaction was cooled to room temperature and filtered. The filtrate was concentrated under reduced pressure to give 6-(1H-pyrazol-1-yl)pyridin-3-amine (600 mg). LCMS (ESI, m / z): 161 [M+H] + .
[0259] Step 3: Synthesis of t-butyl 1-((6-(1H-pyrazol-1-yl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] t-Butyl 1-((6-(1H-pyrazol-1-yl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate was prepared from 6-(t-butoxycarbonyl)-6-azaspiro[2.5]octane-6-carboxylic acid (300 mg), N-(5-aminopyridin-2-yl)acetamide (245 mg), EDCI (248 mg), HOBT (159 mg), and TEA (356 mg) in DCM (3 mL) as described in Step 1 of Example 7 to give t-butyl 1-((6-(1H-pyrazol-1-yl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (300 mg). LCMS (ESI, m / z): 398 [M+H] + .
[0260] Step 4: Synthesis of N-(6-(1H-pyrazol-1-yl)pyridin-3-yl)-6-azaspiro[2.5]octane-1-carboxamide [ka] N-(6-(1H-pyrazol-1-yl)pyridin-3-yl)-6-azaspiro[2.5]octane-1-carboxamide was prepared from t-butyl 1-((6-(1H-pyrazol-1-yl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (300 mg), DCM (6 mL), and HCl (g) (3 mL) as described in Step 2 of Example 13 to give N-(6-(1H-pyrazol-1-yl)pyridin-3-yl)-6-azaspiro[2.5]octane-1-carboxamide (200 mg). LCMS (ESI, m / z): 298 [M+H] + .
[0261] Step 5: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl(±)1-((6-(1H-pyrazol-1-yl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] 1,1,1,3,3,3-Hexafluoropropan-2-yl (±)1-((6-(1H-pyrazol-1-yl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate was prepared from N-(6-(1H-pyrazol-1-yl)pyridin-3-yl)-6-azaspiro[2.5]octane-1-carboxamide (200 mg), ACN (3 mL), 1,1′-carbonyldiimidazole (142 mg), DIPEA (261 mg), and 1,1,1,3,3,3-hexafluoropropan-2-ol (566 mg) as described in Step 3 of Example 1 to afford the title compound (240 mg).
[0262] Example 29: 1,1,1,3,3,3-Hexafluoropropan-2-yl (R or S)-1-((6-(1H-pyrazol-1-yl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate Peak 1 Example 30: 1,1,1,3,3,3-Hexafluoropropan-2-yl (R or S)-1-((6-(1H-pyrazol-1-yl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate Peak 2 [ka] The racemic mixture prepared in Example 28 was purified by chiral HPLC (CHIRALPAK IF, 2 *The two enantiomers were separated by HPLC (25 cm, 5 μm; mobile phase A: Hex (0.5% 2M NH3-MeOH) - HPLC, mobile phase B: EtOH - HPLC; flow rate: 20 mL / min; gradient: 20% B to 20% B in 11 min; UV 220 / 254 nm) to give:
[0263] Example 29: 84.2 mg of 1,1,1,3,3,3-hexafluoropropan-2-yl (R or S)-1-((6-(1H-pyrazol-1-yl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate Peak 1. 1 H NMR(400MHz,chloroform-d)δ 8.55-8.45(m,2H),8.22(d,J=8.5Hz,2H),8.00-7.93(m,1H),7.78-7.65(m,2H),6.51-6.46(m,1H),5.84-5. 72(m,1H),3.81-3.43(m,4H),1.95-1.81(m,2H),1.72-1.53(m,2H),1.53-1.37(m,2H),1.10-1.00(m,1H).t R =5.29 minutes. LCMS (Method G) (ESI, m / z): 492[M+H] + . and the corresponding enantiomers
[0264] Example 30: 86.1 mg 1,1,1,3,3,3-hexafluoropropan-2-yl (R or S)-1-((6-(1H-pyrazol-1-yl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate Peak 2. 1 H NMR(400MHz,chloroform-d)δ 8.55-8.43(m,2H),8.27(d,J=8.5Hz,2H),8.01-7.93(m,1H),7.79-7.64(m,2H),6.50-6.45(m,1H),5.86-5. 70(m,1H),3.80-3.42(m,4H),1.94-1.81(m,2H),1.74-1.53(m,2H),1.55-1.39(m,2H),1.11-0.99(m,1H).t R=7.84 minutes. LCMS (Method E) (ESI, m / z): 492[M+H] + .
[0265] Example 31: 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((6-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] Step 1: Synthesis of 5-amino-N-methylpicolinamide [ka] To a solution of MeNH2 (204 mg, 6.58 mmol, 2.00 equiv) in EtOH (5 mL) was added methyl 5-aminopicolinate (500 mg). The resulting solution was stirred at 80 °C and room temperature overnight and then quenched with water (10 mL). The resulting solution was extracted with EtOAc (3 × 20 mL), and the combined organic layers were washed with brine (1 × 20 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography to give 5-amino-N-methylpicolinamide (400 mg). LCMS (ESI, m / z): 152 [M+H] + .
[0266] Step 2: Synthesis of t-butyl 1-((6-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] t-Butyl 1-((6-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate was prepared from 6-(t-butoxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid (300 mg), 5-amino-N-methylpicolinamide (231 mg), HATU (671 mg), and DIPEA (455 mg) in DMF (5 mL) as described in Step 1 of Example 19 to give t-butyl 1-((6-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (210 mg). LCMS (ESI, m / z): 389 [M+H] + .
[0267] Step 3: Synthesis of N-(6-(methylcarbamoyl)pyridin-3-yl)-6-azaspiro[2.5]octane-1-carboxamide [ka] N-(6-(methylcarbamoyl)pyridin-3-yl)-6-azaspiro[2.5]octane-1-carboxamide was prepared from t-butyl 1-((6-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (210 mg) and HCl (g) (2 mL) in DCM (4 mL) as described in Step 2 of Example 13 to give N-(6-(methylcarbamoyl)pyridin-3-yl)-6-azaspiro[2.5]octane-1-carboxamide (140 mg). LCMS (ESI, m / z): 289 [M+H] + .
[0268] Step 4: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl 1-((6-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] 1,1,1,3,3,3-Hexafluoropropan-2-yl 1-((6-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate was prepared from N-(6-(methylcarbamoyl)pyridin-3-yl)-6-azaspiro[2.5]octane-1-carboxamide (140 mg), ACN (3 mL), 1,1'-carbonyldiimidazole (102 mg), DIPEA (188 mg), and 1,1,1,3,3,3-hexafluoropropan-2-ol (408 mg) as described in Step 3 of Example 1 to give the title compound (160 mg).
[0269] Example 32: 1,1,1,3,3,3-Hexafluoropropan-2-yl (R or S)-1-((6-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate Peak 1 Example 33: 1,1,1,3,3,3-Hexafluoropropan-2-yl (R or S)-1-((6-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate Peak 2 [ka] The racemic mixture prepared in Example 31 was purified by chiral HPLC (CHIRALPAK IF, 2 * The two enantiomers were separated using a 25 cm, 5 μm column; mobile phase A: Hex (0.5% 2M NH3-MeOH) HPLC, mobile phase B: EtOH HPLC; flow rate: 20 mL / min; gradient: 30% B to 30% B in 10.5 min; UV 220 / 254 nm) to give the following:
[0270] Example 32: 33.1 mg of 1,1,1,3,3,3-hexafluoropropan-2-yl (R or S)-1-((6-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate Peak 1. 1H NMR (400 MHz, chloroform-d) δ 8.83 (s, 1H), 8.70-8.46 (m, 1H), 8.39-8.16 (m, 2H), 8.22 (s, 1H), 8.10 (s, 1H), 5.88-5.67 (m, 1H), 3.74 (s, 1H), 3.56 (s, 3H), 3.16-2.97 (m, 3H), 1.87 (s, 2H), 1.79-1.36 (s, 4H), 1.07 (s, 1H). R =6.605 minutes. LCMS (Method A) (ESI, m / z): 483[M+H] + .
[0271] Example 33: 31.8 mg of 1,1,1,3,3,3-hexafluoropropan-2-yl (R or S)-1-((6-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate Peak 2. 1 H NMR (400 MHz, chloroform-d) δ 8.77 (s, 1H), 8.47 (s, 1H), 8.15 (s, 2H), 8.00 (d, J = 5.5 Hz, 1H), 5.86-5.68 (m, 1H), 3.78-3.67 (m, 1H), 3.65-3.47 (m, 3H), 3.04 (d, J = 4.8 Hz, 3H), 1.95-1.79 (m, 2H), 1.78-1.38 (m, 4H), 1.09-1.01 (s, 1H). R =8.899 minutes. LCMS (Method E) (ESI, m / z): 483[M+H] + .
[0272] Example 34: 1,1,1,3,3,3-Hexafluoropropan-2-yl (±) 1-(4-cyclopropylpiperazine-1-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] Step 1: Synthesis of t-butyl 1-(4-cyclopropylpiperazine-1-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] Under nitrogen, a vial was charged with 6-((t-butoxy)carbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid (150 mg), THF (5 mL), 1-cyclopropylpiperazine (74.0 mg), DIPEA (152 mg), and 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane-2,4,6-trione (50% in EtOAc, 563 mg, 0.885 mmol, 1.50 equiv.). The resulting solution was stirred at 60 °C for 3 h and quenched with water (10 mL). The mixture was extracted with EtOAc (3 × 10 mL), and the combined organic layers were washed with brine (3 × 10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was chromatographed on a silica gel column with EtOAc / petroleum ether (2 / 1) to give t-butyl 1-(4-cyclopropylpiperazine-1-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate (57.0 mg). LCMS (ESI, m / z): 364 [M+H] + .
[0273] Step 2: Synthesis of (4-cyclopropylpiperazin-1-yl)(6-azaspiro[2.5]octan-1-yl)methanone [ka] (4-Cyclopropylpiperazin-1-yl)(6-azaspiro[2.5]octan-1-yl)methanone was prepared from t-butyl 1-(4-cyclopropylpiperazin-1-yl)carbonyl)-6-azaspiro[2.5]octane-6-carboxylate (207 mg), DCMe (5 mL), and TFA (5 mL) as described in Step 2 of Example 1 to give the title compound (150 mg). LCMS (ESI, m / z): 264 [M+H] + .
[0274] Step 3: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl(±)1-(4-cyclopropylpiperazine-1-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate [ka] 1,1,1,3,3,3-Hexafluoropropan-2-yl (±)1-(4-cyclopropylpiperazine-1-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate was prepared from 1,1,1,3,3,3-hexafluoropropan-2-ol (287 mg), ACN (5 mL), 1,1′-carbonyldiimidazole (111 mg), and (4-cyclopropylpiperazin-1-yl)(6-azaspiro[2.5]octan-1-yl)methanone (150 mg) as described in Step 3 of Example 1. The crude material was purified by preparative HPLC using the following gradient conditions: 20% CH3CN / 80% A phase, 80% CH3CN in 10 minutes, then ramped to 100% CH3CN in 0.1 minutes, held at 100% CH3CN for 1.9 minutes, then ramped to 20% CH3CN in 0.1 minutes, held at 20% for 1.9 minutes on a Waters 2767-5 chromatograph. Column: X-bridge Prep C 18 , 19 * 150 mm 5 μm; mobile phase: A phase: aqueous NH4HCO3 (0.05%); B phase: CH3CN; detector, UV 220 and 254 nm. Purification yielded 1,1,1,3,3,3-hexafluoropropan-2-yl(±)1-(4-cyclopropylpiperazine-1-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate (80.7 mg). 1 H NMR(300MHz,chloroform-d)δ 5.79-5.74(m,1H),3.38-3.81(m,8H),2.71-2.01(m,4H),1.72-1.58(m,5H),1.2 6-1.53(m,2H),0.85-0.71(m,1H),0.40(br,4H).LCMS(Method E)(ESI,m / z):458[M+H] + .
[0275] Examples 35-189: Examples 35-189 were prepared by procedures similar to those described for Examples 1-34. The absolute configurations of Examples 36, 105, 118, 142, 151, 162, and 174 were determined in a manner similar to that described for Example 3, and resynthesis of the final compounds using intermediates of known absolute configuration allowed the assignment of the absolute configurations of the final products. The stereochemistry of the corresponding (S)-enantiomers (Examples 37, 106, 117, 141, 150, 163, and 175) was assigned as described above for Examples 12, 14, and 17.
[0276] [Table 1]
[0277] [Table 2]
[0278] [Table 3]
[0279] [Table 4]
[0280] [Table 5]
[0281] [Table 6]
[0282] [Table 7]
[0283] [Table 8]
[0284] Table 9
[0285] Table 10
[0286] Table 11
[0287] Table 12
[0288] Table 13
[0289] Table 14
[0290] Table 15
[0291] Table 16
[0292] Table 17
[0293] Table 18
[0294] Table 19
[0295] Table 20
[0296] Table 21
[0297] Table 22
[0298] Table 23
[0299] Table 24
[0300] Table 25
[0301] Table 26
[0302] Table 27
[0303] Table 28
[0304] Table 29
[0305] Table 30
[0306] Table 31
[0307] Table 32
[0308] Table 33
[0309] Table 34
[0310] Table 35
[0311] Table 36
[0312] Table 37
[0313] Table 38
[0314] Table 39
[0315] Table 40
[0316] Table 41
[0317] Table 42
[0318] Table 43
[0319] Table 44
[0320] Table 45
[0321] Table 46
[0322] Table 47
[0323] Table 48
[0324] Table 49
[0325] Table 50
[0326] [Table 51]
[0327] [Table 52]
[0328] [Table 53]
[0329] Example 190-II. Biological Evaluation The compounds were tested to assess their MAGL activity using the following in vitro and in vivo assays.
[0330] In vitro competitive activity-based protein profiling PC3 human cell membrane proteome (50 μL, total protein concentration 2.0 mg / mL) was preincubated with various concentrations of inhibitors at 37°C. After 30 min, the ABPP probe JW912-Bodipy (1.0 μL, 50 μM in DMSO) was added and incubated at room temperature for 30 min. The reaction was quenched with SDS loading buffer (15 μL, 4×) and run on SDS-PAGE. Following gel imaging, serine hydrolase activity was determined by measuring the fluorescence intensity of the gel band corresponding to MAGL using ImageJ 1.43u software. Intensity was converted to percent enzyme activity by normalizing to the DMSO control. IC50 values were determined by fitting percent enzyme activity to a nonlinear regression, four-parameter, sigmoidal dose-response function in Prism GraphPad.
[0331] In vitro competitive substrate hydrolase activity assay HEK293 cell lysates expressing recombinant human MAGL enzyme and 4-nitrophenylacetate (pNPA) substrate were separately diluted in 50 mM HEPES (pH 7.0) containing 200 mM KCl and 1 mM EDTA. Lysates (50 μL, ∼1.2 μg total protein) were preincubated with various concentrations of inhibitor at 25°C. After 30 min, 2× pNPA substrate (50 μL, 2.5 mM) was added, and the rate of substrate turnover was monitored by measuring the increase in absorbance at 405 nm over 20 min at 25°C using a Biotek Neo2 plate reader. Average rates were converted to percent enzyme activity after background subtraction and normalization to the DMSO control. IC50 values were determined by fitting percent enzyme activity to a nonlinear regression, four-parameter, sigmoidal dose-response function in Prism GraphPad.
[0332] In vivo Inhibitors were administered to wild-type C57Bl / 6J mice by oral gavage in a polyethylene glycol vehicle. Animals were sacrificed 4 hours following administration, and brain proteomes were prepared and analyzed according to previously established methods (see Niphakis, MJ, et al. (2011) ACS Chem. Neurosci. and Long, JZ, et al. Nat. Chem. Biol. 5:37-44).
[0333] The compounds demonstrated activity in the assays described herein, as shown in Table 1.
[0334] [Table 54]
[0335] [Table 55]
[0336] [Table 56]
[0337] [Table 57]
[0338] [Table 58]
[0339] Example 191 - Effect of acute treatment in the rat formalin paw model of inflammatory pain In the rat formalin paw model, formalin is administered to the right paw of a rat to induce pain (as measured by the duration and frequency of hind paw licking). Test compounds are administered to assess their efficacy in reducing the frequency of hind paw licking, which is proposed to translate into pain relief, including acute and / or chronic pain, in patients.
[0340] Experimental Protocol: Male Sprague-Dawley rats were divided into three cohorts to allow testing in the Laboras™ instrument to be performed over three days in a balanced design, resulting in 10 treatment groups. On the day of testing, male Sprague-Dawley rats were weighed, tail-marked, and orally administered vehicle, test compound (0.1, 0.3, 0.6, 1, 3, or 10 mg / kg), or pregabalin (30 mg / kg) using a dose volume of 5 mL / kg 4 hours before testing. In Example 6, the vehicle used was 0.5% methylcellulose in water, and in Example 8, the vehicle used was 20% HP-b-CD. A maximum of six animals were administered at a time. Four hours later, the rats received an intraplantar injection of 50 μL of 2.5% v / v formalin solution into the right hind paw. The rats were immediately placed in Laboras™ cages, and data acquisition began. The primary measurements recorded by Laboras™ for the formalin paw model are the duration and frequency of hind paw licking. Locomotion is also reported as maximum speed, average speed during locomotion, or total time bin and distance traveled. After 40 minutes, when data acquisition was complete, rats were removed from their cages.
[0341] After removal from the test cage, rats were anesthetized with the gaseous anesthetic isoflurane (5% v / v isoflurane in oxygen), blood samples were collected by cardiac puncture, and brains were then removed, rinsed in phosphate-buffered saline (PBS), hemisectioned, and frozen separately in liquid nitrogen.
[0342] Data Analysis / Statistics: Data were analyzed using Statistica software (TIBCO, USA, version 11.1). All data are expressed as mean ± standard error of the mean (sem) to one decimal point. Data are presented as total activity from 0 to 10 min (early inflammatory phase) and 10 to 30 min (delayed inflammatory phase), as well as time course data in 5-min time bins for the entire 40 min of data collection.
[0343] Time course data were analyzed by repeated measures analysis of variance (ANOVA) followed by one-way ANOVA for each time point, followed by Dunnett's post-hoc test. The early and delayed inflammatory phases of these data were analyzed by one-way ANOVAs and Dunnett's post-hoc test.
[0344] Outliers were defined as values greater than two standard deviations from the mean and were excluded for the 0-10 min and 10-30 min data, as well as the time course data. The significance level was set at p<0.05.
[0345] As shown in Figure 1, administration of Example 6 at 0.6 mg / kg, 3 mg / kg, and 10 mg / kg resulted in a statistically significant decrease in spontaneous pain measurements (hind paw licking frequency) in the early and / or late stages of the study. As shown in Figure 2, administration of Example 8 at 1 mg / kg, 3 mg / kg, and 10 mg / kg resulted in a statistically significant decrease in spontaneous pain measurements (hind paw licking frequency) in both the early and late stages of the study, and further administration of Example 8 at 0.3 mg / kg and 0.6 mg / kg resulted in a statistically significant decrease in spontaneous pain measurements in the late stage.
[0346] Example 192 - Evaluation of the effects of compounds of the present invention in the Maximum Electroshock Epileptic Seizure Threshold (MEST) model in rats Experimental Protocol: In the MEST model, high-frequency, short-duration, low-intensity electrical current is applied to induce tonic seizures. The MEST test allows for the identification of anticonvulsant activity in compounds that may be useful in treating generalized epileptic seizures.
[0347] Animals were randomly assigned to vehicle, compound treatment, or lamotrigine treatment groups.
[0348] Animals were administered 5 mL / kg of either vehicle (0.5% MC) orally for Example 6, vehicle (10% HP-b-CD) for Example 8, test compound 10 mg / kg orally (240 min before treatment), or lamotrigine orally (360 min before treatment) according to treatment group (n=12 or 16 / group).
[0349] Rats were individually assessed for the occurrence of tonic hindlimb extensor seizures following a single corneal delivered electric shock of 0.3 seconds duration using the "up and down" method of shock titration (Kimball AW et al., 1957). Thus, the first rat within a treatment group was shocked at the expected or estimated CC50 current (the current that will produce tonic hindlimb extensor seizures in 50% of animals). Subsequent animals were assessed for a log 0.06:10^(1+× ) difference if the preceding rat exhibited or did not exhibit tonic hindlimb extension, respectively. * The stimulation intensity was decreased or increased in steps of 0.06 mA. This procedure was continued for all rats within a treatment group. Seizure induction was measured as an all-or-none effect, scored as either present (+) or absent (0) for each animal.
[0350] Data for each treatment group were recorded as the number of +s and 0s at each current level employed, and the information was then used to calculate CC50 values (the current required for 50% of animals to exhibit tonic hindlimb extension) ± standard error according to the method of Kimball et al. (1957). Drug effects were calculated as the percent change in CC50 from the vehicle control group.
[0351] Statistical analysis: Significant differences between drug-treated animals and controls were assessed according to Litchfield and Wilcoxon (1949) or one-way ANOVA followed by Dunnett's multiple comparison test.
[0352] result: The results suggest that Examples 6 and 8 have anticonvulsant activity at 10 mg / kg in the MEST in rats (FIGS. 3 and 4, respectively).
[0353] Example 193 - Evaluation of test compounds for anticonvulsant activity in the kainic acid seizure model in rats Kainic acid is an analog of the excitatory neurotransmitter glutamate and functions as an agonist at kainate receptors. After systemic injection, kainic acid induces a prolonged excitatory response with many characteristics of human temporal lobe epilepsy.
[0354] Experimental Protocol: The method for detecting anticonvulsant activity associated with glutamatergic mechanisms follows that described by Ben-Ari et al. (Neuroscience, 6, 1361-1391, 1981).
[0355] Rats placed in individual Plexiglas cages (33 x 21 x 18 cm) are injected with kainic acid (20 mg / kg i.p.). The occurrence of the following symptoms is recorded for 120 min starting 30 min after kainic acid injection: forelimb clonus, rearing and rearing with falls, clonic convulsions, tonic convulsions, and death. The presence of each symptom and the latency to the first appearance of the symptom are measured. The number of forelimb clonus episodes is counted.
[0356] Twelve rats are tested per group and the study is performed in a partially blinded manner.
[0357] Test substances are evaluated in multiple doses, administered orally 240 minutes before testing and compared to a corresponding vehicle control group (Group 2, 10% HP-b-CD in distilled water administered orally 240 minutes before testing).
[0358] Example 6 was orally administered at 0.3, 1, 3, and 10 mg / kg, and Example 8 was orally administered at 1, 3, and 10 mg / kg 4 hours before the test, and evaluated in comparison with the vehicle control group (10% HP-b-CD was orally administered 4 hours before the test).
[0359] Diazepam (16 mg / kg), used as a reference substance, was administered orally 60 min before testing (0.5% HP-b-CD) and compared with vehicle control.
[0360] Data Analysis / Statistics: Quantitative data (latency periods) for test substances were analyzed by comparing treatment groups with vehicle controls using the Kruskal-Wallis test followed by the Mann-Whitney U test. Quantitative data for reference substances were analyzed using the Mann-Whitney U test.
[0361] Numerical data (frequencies) were analyzed using Fisher's exact test by comparing treatment groups with vehicle controls.
[0362] The results suggest clear anticonvulsant effects for Example 6 over the dose range of 0.3-10 mg / kg and for Example 8 over the dose range of 1-10 mg / kg in the kainic acid seizure test in rats. The magnitude of the effects of the compounds of Examples 6 and 8 at mid- and high doses was close to that observed with the reference substance diazepam.
[0363] Example 194 - Rat Kp Brain quality was assessed in male Sprague-Dawley rats (n = 3, normal weight). Briefly, test compounds were formulated as a simple suspension in 0.5% HPMC in water and then administered by oral gavage (5 mg / kg, 5 mL / kg). Four hours after administration, rats were sacrificed, and terminal blood and brain samples were collected. Blood was collected via cardiac puncture (0.1 mL) and immediately placed in 0.4 mL of CH3CN for sedimentation. Samples were stored at -75 + / - 15 °C prior to analysis. After complete exsanguination of the animals, brain tissue samples were collected, and the tissue was quickly washed with cold saline. After sectioning, brain sections were immediately frozen in liquid nitrogen and stored at -75 + / - 15 °C prior to analysis. Blood and brain samples were analyzed by LC / MS / MS using the optimal analytical method. Concentrations of test substances in blood and brain were quantified against matrix-matched calibration standards. Calculated Brain K p (total brain concentration:total plasma concentration ratio), calculated brain k p,uu The whole blood, plasma, and brain concentration data, along with the unbound brain concentration:unbound plasma concentration ratio, rat plasma and brain free fraction, and ex vivo rat blood-to-plasma distribution profile, are shown in Table 2. The total plasma concentration data were calculated from the total blood concentration data using the ex vivo measured rat blood-to-plasma ratio (1 μM test compound). p,uu To determine the free fraction in rat plasma and brain homogenates, the free fraction was measured in vitro by standard equilibrium dialysis (1 μM test substance, equilibrated for 6 hours against buffer pH 7.4; for rat plasma analysis, a 100 mM stock solution of diisopropyl fluorophosphate was added to prewarmed rat plasma before addition of the test substance).
[0364] [Table 59]
[0365] Example 195 - Solubility (Kinetic) The kinetic solubility of test substances was determined in duplicate in PBS at pH 2.0 and pH 7.4. Stock solutions of test compounds in DMSO (10 mM) were incubated at room temperature for 2 hours with shaking at 1,100 RPM. Samples were then filtered using a vacuum manifold, diluted, and analyzed by LC-MS / MS. Chromatographic conditions: Phenomenex Synergi 4μ Hydro-PR 80A column (2.0 × 30 mm) coupled with a Preguard column; mobile phase = 0.1% formic acid in acetonitrile and 0.1% formic acid in water; flow rate = 0.65 mL / min; column temperature = 40 °C; injection volume: 3 μL.
[0366] [Table 60]
[0367] Mass conditions: turbospray ion source; ESI ionization model; MRM scan type; collision gas = 6 L / min; curtain gas = 30 L / min; nebulizer gas = 50 L / min; auxiliary gas = 50 L / min; temperature = 500 °C; ion spray voltage = +5500 V (positive MRM).
[0368] The filtered solutions were analyzed and quantified against standards of known concentration in DMSO using UPLC coupled with mass spectral peak identification and quantification. Solubility values for the test substances were calculated using Microsoft Excel as follows (DF is the dilution factor):
number
[0369] The kinetic solubility data are presented in Table 3.
[0370] [Table 61]
[0371] Example 196 - Solubility (thermodynamic) The thermodynamic solubility of test articles was determined in duplicate in PBS at pH 7.4. Test substances (1.5 mg) in PBS were incubated at room temperature for 24 hours with shaking at 1100 rpm. Samples were then filtered using a vacuum manifold, diluted, and analyzed by LC-MS / MS. Chromatographic conditions: Phenomenex Synergi 4μ Hydro-PR 80A column (2.0 × 30 mm) coupled with a Preguard column; mobile phase = 0.1% formic acid in acetonitrile and 0.1% formic acid in water; flow rate = 0.65 mL / min; column temperature = 40°C; injection volume: 10 μL.
[0372] [Table 62]
[0373] Mass conditions: turbospray ion source; ESI ionization model; MRM scan type; collision gas = 6 L / min; curtain gas = 30 L / min; nebulizer gas = 50 L / min; auxiliary gas = 50 L / min; temperature = 500 °C; ion spray voltage = +5500 V (positive MRM).
[0374] The filtered solutions were analyzed and quantified against standards of known concentration in DMSO using UPLC coupled with mass spectral peak identification and quantification. Solubility values for the test substances were calculated using Microsoft Excel as follows (DF is the dilution factor):
number
[0375] Thermodynamic solubility data are presented in Table 4.
[0376] [Table 63]
[0377] Example 197 - Stability of human hepatocytes in vitro Commercially sourced pooled donor cryopreserved human hepatocytes (0.5 × 106 The metabolic stability of test articles (1 μM) in CL cells / mL was determined in duplicate. int The reaction (250 μL) was initiated. Aliquots (25 μL) were withdrawn at 0, 15, 30, 45, 60, 90, 120, and 240 min. The protein was then crushed with ice-cold acetonitrile containing an internal standard and then centrifuged (3220 g, 25 min). The supernatant was used for LC-MS / MS analysis. The in vitro half-life (in vitro t) was calculated as the slope value: in vitro t 1 / 2 =-0.693 / k. 1 / 2 Conversion of the measured values (units: min) to scaled-up unbound intrinsic clearance (scaled-up unbound CLint, units: mL / min / kg) was performed using the data shown in Table 5 using the following formula (average of duplicate measurements): scaled-up unbound CLint = kV / N × scaling factor; V = incubation volume (0.25 mL); N = number of hepatocytes per well (0.125 × 10 5 The predicted in vivo intrinsic clearance factors are shown below:
[0378] [Table 64]
[0379] [Table 65]
Claims
1. Formula (I): [Formula 1] (In the formula, R1 is -C(O)NHR2, -C(O)N(CH 3 )R2, -C(O)NR3R4, -C(O)NHCH 2 R2, or -C(O)NHC(O)R2; R2 is phenyl, or a 5- or 6-membered heteroaryl having 1 or 2 heteroatoms independently selected from N, O, and S; a 6-membered heterocycle having 1 or 2 heteroatoms independently selected from N or O; 3 ~C 7 represents a 7-membered bicyclic heterocycle having 1 or 2 heteroatoms independently selected from cycloalkyl, N, or O; R3 and R4 together with the N to which they are attached form a 9- or 10-membered bicyclic heterocycle having 1 to 4 heteroatoms independently selected from N or O, or a 6-membered heterocycle having 1 or 2 heteroatoms independently selected from N or O; each phenyl, 5- or 6-membered heteroaryl, 6-membered heterocycle, C 3 ~C 7 The cycloalkyl, 7-membered bicyclic heterocycle, or 9- or 10-membered bicyclic heterocycle is unsubstituted or is selected from the group consisting of halogen, C 1 ~C 3 Alkyl, C 1 ~C 3 Haloalkyl, C 3 ~C 6 Cycloalkyl, C 1 ~C 3 Alkoxy, cyano, -NHC(O)CH 3 , -C(O)NH 2 , -C(O)NHCH 3 , a 5-membered heteroaryl having 1 or 2 heteroatoms independently selected from N or O, —NHSO 2 CH 3 , -P(O)(CH 3 ) 2 , and -OCH 2or a pharma- ceutically acceptable salt thereof.
2. Formula (Ia): [Case 2] (In the formula, R1 is -C(O)NHR2, -C(O)N(CH 3 )R2, -C(O)NR3R4, -C(O)NHCH 2 R2, or -C(O)NHC(O)R2; R2 is phenyl, or a 5- or 6-membered heteroaryl having 1 or 2 heteroatoms independently selected from N, O, and S; a 6-membered heterocycle having 1 or 2 heteroatoms independently selected from N or O; 3 ~C 7 represents a 7-membered bicyclic heterocycle having 1 or 2 heteroatoms independently selected from cycloalkyl, N, or O; R3 and R4 together with the N to which they are attached form a 9- or 10-membered bicyclic heterocycle having 1 to 4 heteroatoms independently selected from N or O, or a 6-membered heterocycle having 1 or 2 heteroatoms independently selected from N or O; each phenyl, 5- or 6-membered heteroaryl, 6-membered heterocycle, C 3 ~C 7 The cycloalkyl, 7-membered bicyclic heterocycle, or 9- or 10-membered bicyclic heterocycle is unsubstituted or is selected from the group consisting of halogen, C 1 ~C 3 Alkyl, C 1 ~C 3 Haloalkyl, C 3 ~C 6 Cycloalkyl, C 1 ~C 3 Alkoxy, cyano, -NHC(O)CH 3 , -C(O)NH 2 , -C(O)NHCH 3 , a 5-membered heteroaryl having 1 or 2 heteroatoms independently selected from N or O, —NHSO 2 CH 3 , -P(O)(CH 3 ) 2 , and -OCH 2 2. The compound of claim 1 having the structure:
3. A compound according to any one of claims 1 to 2, wherein R1 represents -C(O)NHR2, or a pharma- ceutically acceptable salt thereof.
4. R2 represents a 5- or 6-membered heteroaryl selected from the group consisting of pyridyl, pyrazinyl, pyridazinyl, pyrimidyl, pyrazolyl, thiazolyl, and isoxazolyl, wherein the 5- or 6-membered heteroaryl is unsubstituted or is selected from the group consisting of halogen, C 1 ~C 3 Alkyl, C 1 ~C 3 Haloalkyl, cyclopropyl, C 1 ~C 3 Alkoxy, cyano, -NHC(O)CH 3 , -C(O)NH 2 , -C(O)NHCH 3 , a 5-membered heteroaryl having 1 or 2 heteroatoms independently selected from N or O, —NHSO 2 CH 3 , -P(O)(CH 3 ) 2 , and -OCH 2 The compound according to any one of claims 1 to 3, or a pharma- ceutically acceptable salt thereof, substituted by one substituent selected from the group consisting of COOH.
5. R2 represents a 6-membered heterocycle selected from the group consisting of tetrahydro-2H-pyran-4-yl, piperazinyl, and piperidinyl, wherein R2 is unsubstituted or 1 ~C 3 Alkyl, C 3 ~C 6 The compound according to any one of claims 1 to 3, or a pharma- ceutically acceptable salt thereof, which is substituted by one substituent selected from the group consisting of cycloalkyl, and cyano.
6. The compound according to any one of claims 1 to 5, wherein R2 represents a 6-membered heterocycle selected from the group consisting of tetrahydro-2H-pyran-4-yl, piperazinyl, and piperidinyl, and said R2 is unsubstituted, or a pharma- ceutically acceptable salt thereof.
7. Formula (Ic): [C3] (In the formula, R5 is phenyl, or a 5- or 6-membered heteroaryl having 1 or 2 heteroatoms independently selected from N, O, and S; a 6-membered heterocycle; 3 ~C 7 represents a 7-membered bicyclic heterocycle having 1 or 2 heteroatoms independently selected from cycloalkyl, N, or O; R6 represents hydrogen or methyl; W is -CH 2 - or -C(O)-; n is 0 or 1; each phenyl, 5- or 6-membered heteroaryl, 6-membered heterocycle, C 3 ~C 7 Cycloalkyl, 7-membered bicyclic heterocycle is unsubstituted or is selected from halogen, C 1 ~C 3 Alkyl, C 1 ~C 3 Haloalkyl, C 3 ~C 6 Cycloalkyl, C 1 ~C 3 Alkoxy, cyano, -NHC(O)CH 3 , -C(O)NH 2 , -C(O)NHCH 3 , a 5-membered heteroaryl having 1 or 2 heteroatoms independently selected from N or O, —NHSO 2 CH 3 , -P(O)(CH 3 ) 2 , and -OCH 2 3. The compound according to claim 1, having the structure:
8. 8. The compound of claim 7, or a pharma- ceutically acceptable salt thereof, wherein n is 0.
9. R5 represents a 5- or 6-membered heteroaryl selected from the group consisting of pyridyl, pyrazinyl, pyridazinyl, pyrimidyl, pyrazolyl, thiazolyl, and isoxazolyl, wherein the 5- or 6-membered heteroaryl is unsubstituted or selected from the group consisting of halogen, C 1 ~C 3 Alkyl, C 1 ~C 3 Haloalkyl, cyclopropyl, C 1 ~C 3 Alkoxy, cyano, -NHC(O)CH 3 , -C(O)NH 2 , -C(O)NHCH 3 , a 5-membered heteroaryl having 1 or 2 heteroatoms independently selected from N or O, —NHSO 2 CH 3 , -P(O)(CH 3 ) 2 , and -OCH 2 The compound according to any one of claims 7 to 8, or a pharma- ceutically acceptable salt thereof, substituted by one substituent selected from the group consisting of COOH.
10. The compound according to any one of claims 7 to 9, or a pharma- ceutically acceptable salt thereof, wherein R5 represents a 6-membered heteroaryl selected from the group consisting of pyridyl, pyrazinyl, pyridazinyl, and pyrimidyl, and said 6-membered heteroaryl is unsubstituted.
11. R5 represents a 6-membered heterocycle selected from the group consisting of tetrahydro-2H-pyran-4-yl, piperazinyl, and piperidinyl, wherein R5 is unsubstituted or 1 ~C 3 Alkyl, C 3 ~C 6 The compound according to any one of claims 7 to 8, or a pharma- ceutically acceptable salt thereof, which is substituted by one substituent selected from the group consisting of cycloalkyl and cyano.
12. 12. The compound of any one of claims 7 to 11, or a pharma- ceutically acceptable salt thereof, wherein R5 is unsubstituted.
13. 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((tetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(methyl(pyrazin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(isoxazol-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((2-(trifluoromethyl)pyrimidin-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((6-(dimethylphosphoryl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(pyridin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((tetrahydro-2H-pyran-4-carbonyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((6-(1H-pyrazol-1-yl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((6-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(4-cyclopropylpiperazine-1-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((6-methoxypyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((5-fluoropyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(methyl(pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(methyl(pyridin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(pyridin-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (±) 1-(2-(trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-7-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(pyrazin-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(2-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-7-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-6-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(2-cyclopropyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-6-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((5-chloropyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((2-methylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((6-(trifluoromethyl)pyridin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(((6-(trifluoromethyl)pyridin-2-yl)methyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((6-(trifluoromethyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((6-methylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((2-(trifluoromethyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((pyridin-3-ylmethyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((cyclohexanecarbonyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(benzoylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(pyrimidin-5-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((2-(trifluoromethyl)pyrimidin-5-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((2-methylpyrimidin-5-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((6-methylpyridazin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(pyridazin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((5-methylpyrazin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((1-methylpiperidin-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(((tetrahydro-2H-pyran-4-yl)methyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(morpholine-4-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(4-cyanopiperidine-1-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((1-methyl-1H-pyrazol-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(thiazol-5-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((4-methyltetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((1-methyl-1H-pyrazol-5-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(thiazol-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(phenylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(p-tolylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (±)-1-((3-fluorophenyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate: 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(benzylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((pyrimidin-5-ylmethyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((pyridazin-3-ylmethyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((2-oxaspiro[3.3]heptan-6-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((6-cyclopropylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((6-isopropoxypyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(((4-methyltetrahydro-2H-pyran-4-yl)methyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((6-acetamidopyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((6-carbamoylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(isoxazol-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((6-(methylsulfonamido)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; (±) 2-((5-(6-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-6-azaspiro[2.5]octane-6-1-carboxamido)pyridin-2-yl)oxy)acetic acid; 1,1,1,3,3,3-Hexafluoropropan-2-yl (±) 1-(3-cyclopropyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine-7-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-7-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-7-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-(methyl(pyridazin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; and 1,1,1,3,3,3-Hexafluoropropan-2-yl(±)1-((6-cyanopyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate 2. The compound of claim 1 selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.
14. 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((tetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-((tetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(methyl(pyrazin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(methyl(pyrazin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(isoxazol-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(isoxazol-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((2-(trifluoromethyl)pyrimidin-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-((2-(trifluoromethyl)pyrimidin-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((6-(dimethylphosphoryl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-((6-(dimethylphosphoryl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(pyridin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(pyridin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((tetrahydro-2H-pyran-4-carbonyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-((tetrahydro-2H-pyran-4-carbonyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((6-(1H-pyrazol-1-yl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-((6-(1H-pyrazol-1-yl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((6-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-((6-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((6-methoxypyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-((6-methoxypyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-hexafluoropropan-2-yl (R)-1-((5-fluoropyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-((5-fluoropyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(methyl(pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(methyl(pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(methyl(pyridin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(methyl(pyridin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(pyridin-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(pyridin-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(2-(trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-7-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(2-(trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-7-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(pyrazin-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(pyrazin-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(2-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-7-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(2-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-7-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-hexafluoropropan-2-yl (R)-1-(5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-6-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-6-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-hexafluoropropan-2-yl (R)-1-(2-cyclopropyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-6-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(2-cyclopropyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-6-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-hexafluoropropan-2-yl (R)-1-((5-chloropyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-((5-chloropyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((2-methylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-((2-methylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((6-(trifluoromethyl)pyridin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-((6-(trifluoromethyl)pyridin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-hexafluoropropan-2-yl (R)-1-(((6-(trifluoromethyl)pyridin-2-yl)methyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(((6-(trifluoromethyl)pyridin-2-yl)methyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((6-(trifluoromethyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-((6-(trifluoromethyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((6-methylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-((6-methylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((2-(trifluoromethyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-((2-(trifluoromethyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((pyridin-3-ylmethyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-((pyridin-3-ylmethyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((cyclohexanecarbonyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-((cyclohexanecarbonyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(benzoylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(benzoylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(pyrimidin-5-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(pyrimidin-5-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((2-(trifluoromethyl)pyrimidin-5-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-((2-(trifluoromethyl)pyrimidin-5-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((2-methylpyrimidin-5-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-((2-methylpyrimidin-5-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((6-methylpyridazin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-((6-methylpyridazin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(pyridazin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(pyridazin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((5-methylpyrazin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-((5-methylpyrazin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((1-methylpiperidin-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-((1-methylpiperidin-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(((tetrahydro-2H-pyran-4-yl)methyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(((tetrahydro-2H-pyran-4-yl)methyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(morpholine-4-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(morpholine-4-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(4-cyanopiperidine-1-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(4-cyanopiperidine-1-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((1-methyl-1H-pyrazol-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-((1-methyl-1H-pyrazol-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(thiazol-5-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(thiazol-5-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((4-methyltetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-((4-methyltetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((1-methyl-1H-pyrazol-5-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-((1-methyl-1H-pyrazol-5-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(thiazol-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(thiazol-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(phenylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(phenylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(p-tolylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(p-tolylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((3-fluorophenyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-((3-fluorophenyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(benzylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(benzylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((pyrimidin-5-ylmethyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((pyrimidin-5-ylmethyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((pyridazin-3-ylmethyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-((pyridazin-3-ylmethyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-hexafluoropropan-2-yl (R)-1-((2-oxaspiro[3.3]heptan-6-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-((2-oxaspiro[3.3]heptan-6-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((6-cyclopropylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-((6-cyclopropylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((6-isopropoxypyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-((6-isopropoxypyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-hexafluoropropan-2-yl (R)-1-(((4-methyltetrahydro-2H-pyran-4-yl)methyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(((4-methyltetrahydro-2H-pyran-4-yl)methyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((6-acetamidopyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-((6-acetamidopyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((6-carbamoylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-((6-carbamoylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-(isoxazol-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(isoxazol-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (R)-1-((6-(methylsulfonamido)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-((6-(methylsulfonamido)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; (R)-2-((5-(6-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-6-azaspiro[2.5]octane-1-carboxamido)pyridin-2-yl)oxy)acetic acid; and (S)-2-((5-(6-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-6-azaspiro[2.5]octane-1-carboxamido)pyridin-2-yl)oxy)acetic acid 2. The compound of claim 1, selected from the group consisting of:
15. The compound according to claim 1, which is 1,1,1,3,3,3-hexafluoropropan-2-yl (S)-1-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate, or a pharma- ceutically acceptable salt thereof.
16. The compound according to claim 1, which is 1,1,1,3,3,3-hexafluoropropan-2-yl (S)-1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate, or a pharma- ceutically acceptable salt thereof.
17. The compound according to claim 1, which is 1,1,1,3,3,3-hexafluoropropan-2-yl (S)-1-(isoxazol-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate, or a pharma- ceutically acceptable salt thereof.
18. A pharmaceutical composition comprising a compound according to any one of claims 1 to 17, or a pharma- ceutically acceptable salt thereof, and one or more pharma- ceutically acceptable carriers or diluents.
